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Copper (Cu) is a key micronutrient required for a variety of essential bio-
chemical pathways. Systemic or tissue-specific Cu-deficiencies, caused by insuffi-
cient dietary Cu uptake or mutations in Cu transporting genes, result in impaired
growth, neuropathy, ataxia, hypopigmentation, osteoporosis and anemia-like symp-
toms in mammals. How organisms regulate Cu homeostasis at the systemic levels
in response to Cu deficiencies remain elusive. In this study, we use Caenorhabdi-
tis elegans (C. elegans), a genetically tractable, multi-tissue metazoan to explore
Cu homeostasis and investigate these unknowns. The high-affinity Cu transporters
encoded by CTR family genes are required for dietary Cu uptake and maintaining
systemic Cu balance from yeast to mammals. However, little is known about Cu
acquisition mechanisms in C. elegans. We identified ten CTR ortholog genes in C.
elegans; of these, chca-1 was functionally characterized. Cu availability regulates
transcription of chca-1 in both the intestine and hypodermis, and chca-1 is essential
for normal growth, and reproduction in the worm. Additionally, altered Cu balance
caused by the loss of CHCA-1 results in defects in Cu-responsive avoidance behav-
ior. Identification of this CTR-like gene in C. elegans, which appears to be essential
for normal Cu homeostasis in the worm, illustrates the importance of Cu delivery
via CHCA-1 for normal metazoan development and behavioral phenotypes. In addi-
tion, we show that a Cu-binding pharmacological chaperone, elesclomol (ES), fully
restores the developmental defects and Cu deficiencies in chca-1 -depleted worms,
as well as the lethality in worms lacking cua-1 expression (Cu exporter ATP7A
ortholog), suggesting ES is able to efficiently deliver Cu from dietary sources to pe-
ripheral tissues through the intestine in C. elegans. Our study was further expanded
to mammalian models such as cardiac-specific Ctr1 -depleted (Ctr1hrt/hrt) mice. We
found that ES administration fully restores the postnatal lethality, developmental
defects and cardiac hypertrophy found in Ctr1hrt/hrt mice, as well as rescuing the
secondary systemic Cu homeostasis responses, including aberrant ATP7A protein
levels in the liver and intestine. Moreover, ES shows the potential ability to trans-
port Cu across the blood-brain-barrier in in vitro studies. These results illustrate
the capability of ES to rescue systemic Cu deficiency in worms and mice, indepen-
dent of the presence of functional Cu transporters, and shed light on the therapeutic
usage of ES in Cu-deficient human diseases.
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Copper (Cu) is a crucial micronutrient required for a wide range of catalytic
reactions in living organisms. It serves as a cofactor in Cu-dependent enzymes
necessary for mitochondrial ATP synthesis, iron homeostasis, myelination, pigmen-
tation, neurotransmission and various other physiological processes [1, 2, 3, 4]. Most
of these Cu-dependent catalytic reactions involve the redox change between Cu(I)
and Cu(II). Dietary Cu deficiency or mutations in genes regulating Cu homeostasis
can lead to diseased states such as poor growth and development, and cognitive
disorders[5, 6]. However, Cu overload can also be toxic to both eukaryotic and
prokaryotic cells, as cycling between the two redox states can yield highly toxic free
radicals through Fenton reactions. Cu is additionally reactive to thiol groups and
may disrupt protein structure upon binding when presence in excess [7, 8, 9]. There-
fore, organisms have adopted elaborate Cu homeostatic mechanisms to regulate Cu
uptake, detoxification, and distribution at both the cellular and systemic levels.
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1.1 Cellular Cu homeostasis
1.1.1 Cu uptake
Before entering the cells, Cu is thought to first be reduced from the Cu(II) to
the Cu(I) state by a metalloreductase. In Saccharomyces cerevisiae, the FRE family
of reductases facilitates both iron (Fe) and Cu reduction [10]. In mammalian cells,
Steap2, Steap3, Steap4 and DcytB function both as ferric and cupric reductase in
vitro [11, 12]. The in vivo functions of these metalloreductase in Cu uptake are yet
to be confirmed.
Cu(I) is imported into eukaryotic cells by the membrane-bound high-affinity
copper uptake protein (Ctr). Ctr was first identified in yeast and plant, leading to
the discovery of several Ctr family members in humans, mice, fruit flies, and other
species by homology searches and functional complementary studies [13]. All charac-
terized Ctr proteins contain a methionine (Met)-rich extracellular amino-terminus
and three putative transmembrane domains (TMD) with a Met-X3-Met domain
within or close to the second TMD. Electron crystallography revealed that human
Ctr1 (hCtr1) can form trimers at the plasma membrane [14, 15, 16]. The extracel-
lular N-terminal methionine-rich domain, the Met-X3-Met motif and the cytosolic
C-terminal Cys-His-Cys motif are potential Cu binding sites necessary for effective
Cu transport [17, 18, 19]. Furthermore, hCtr1 is both N-linked and O-linked glycosy-
lated at the amino terminus at positions Asn15 and Thr27. Glycosylation stabilizes
and protects Ctr1 from truncation and internalization [20, 21]. Ctr1 also contains an
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Figure 1.1: Predicted topology of human CTR1 and ATP7A. A) Topological model
of CTR1 reveals three transmembrane domains with an extracellular Met- and His-
enriched N-terminus. The N-terminus also contains two glycosylation sites. The
Met-X3-Met motif is conserved for Cu transport. B) ATP7A contains eight trans-
membrane domains and an intracellular N-terminus which has six Cu-binding do-
mains. Other highly conserved domains including the phosphatase (A domain),
phosphorylation (P-domain) and ATP-binding (N-domain) domains. The dileucine
(LL) motif close to the C-terminus is required for internalization.
3
A                                                
B
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AP2 µ2 subunit binding motif, TNSM, in the C-terminus that potentially mediates
clathrin-dependent endocytosis [22] (Figure 1.1A).
In human cells, the Km of Ctr1 for Cu uptake ranges from 1-10 µM [14, 23],
with high metal specificity. The uptake efficiency can be influenced by extracellular
pH, as well as Cu and potassium concentrations in vitro. In addition to Ctr1, the
human zinc importer, hZIP4, has been demonstrated to have Cu(II) transportation
activity in vitro [24]. While structural models indicate that hCtr1 contains a pore-
like structure similar to ion channels, Ctr1 exhibits concentration-dependent Cu up-
take and saturates at a rate of ∼10 ions/s in kinetic assays. This rate is consistent
with other transporter proteins, rather than channels that capable of transporting
close to the rate of diffusion at ∼ 108 ions/s [14, 15, 16, 25, 26]. Organisms may co-
ordinate multiple Ctr orthologs in order mediate Cu uptake. varying Ctr homologs
may be enriched in different cellular localizations, expressed in distinct tissues, ex-
pressed during different developmental stages, or as determined by Cu availability.
For example, Drosophila melanogaster expresses three Ctr1 genes, Ctr1A, Ctr1B,
and Ctr1C. While Ctr1A is ubiquitously and constitutively active through the whole
body and all developmental stages, Ctr1B is essential for intestinal Cu uptake in
early-mid larvae stages and is transcriptionally upregulated by Cu-deficiency, and
Ctr1C functions to transport Cu into the male germline [27, 28, 29]. Yeast Ctr1
and Ctr3 localize to the plasma membrane for Cu intake, and Ctr2 localizes to the
vacuolar membrane, suggesting its role is to export Cu from vacuoles [18, 30]. Yeast
CTR1 is transcriptionally upregulated by low Cu through binding of the Mac1 tran-
scription factor to the CTR1 promoter (CuRE). D. melanogaster Ctr1B transcripts
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are induced under Cu deprivation via the transcription factor MTF-1 [31, 32].
Mouse and human genomes harbor two Ctr homologs, Ctr1 and Ctr2. Ctr2
shares high sequence and structural similarity to Ctr1, but contains a shorter extra-
cellular N-terminus. While Ctr1 localizes to the plasma membrane and intracellular
vesicles required for dietary Cu absorption, Ctr2 is enriched in endosomes, facilitates
truncation of the Ctr1 N-terminus ectodomain via Cathepsin B/L proteases, and
potentially mediates Cu export from emdosomes via truncated Ctr1 [33, 34]. In ad-
dition, it has been reported that Ctr1 and Ctr2 physically interact with each other
and Ctr2 protein stability depends on the presence of Ctr1 [35]. In mammals, there
is no evidence of transcriptional regulation of Ctr1 by Cu. Instead, mammalian
Ctr1 subcellular localization and protein stability are regulated post-translationally.
When Cu abundance increases, plasma membrane localized Ctr1 undergoes clathrin-
dependent endocytosis and proteasome-mediated posttranslational degradation, in
order to prevent excessive Cu accumulation [26, 36]. In mice, depletion of the
Cu chaperone Sco1 for mitochondria cytochrome c oxidase assembly induces Ctr1
turnover in the liver as well as Ctr1 mislocalization in the heart, [37, 38].
Cu acquisition via Ctr1 is vital to maintaining cellular and systemic Cu home-
ostasis. Depleting Ctr1 in mice and zebrafish results in lethality at the embryonic
stage [39, 40]. Conditional knockout of this gene in the mouse intestine leads to se-
vere viability defects due to Cu deficiency in peripheral tissues, cardiac hypertrophy,
and accumulation of non-bioavailable Cu in the intestine [41].
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1.1.2 Cu delivery to the secretory pathway and efflux via ATP7A/B
ATP7A and ATP7B are two mammalian P-type ATPases that are required for
delivering Cu(I) to several newly synthesized cuproenzymes in the trans Golgi net-
work (TGN), and exporting excess Cu from cells via the plasma membrane. ATP7A
and ATP7B share around 60% DNA sequence homology and exhibit comparable
topology. They are both transmembrane proteins containing eight TMDs, with the
N- and C-termini both facing the cytosolic side of the membrane. Cu can associate
with the six metal binding domains (MBD) present in the N-terminus, with each do-
main containing a conserved Met-X-Cys-X2-Cys Cu-binding site [42, 43, 44]. These
P-type ATPases harbor another metal binding site, the M domain, and Cu binding
to the M domain is necessary to trigger ATPase-dependent Cu transport. Several
conserved domains, including the Cys-Pro-Cys (CPC) in TMD6, the Asp-Tyr (YN)
in TMD7 and TMD8 Met-X2-Ser (MxxS) motifs are required to incorporate Cu
into the M domain. During one catalytic cycle, ATP first binds to the ATP-binding
domain (N) and Cu(I) binds to the MBD and M domains. Next, ATP is phospho-
rylated in the phosphorylation domain (P) at the Asp-Lys-Thr-Gly (DKTG) motif,
which is coupled with the release of Cu(I). The cycle is then finished by the dephos-
phorylation of the intermediates in the actuator domain (A) [45, 46]. In addition,
the C-terminus of ATP7A/B contains a dileucine motif required for trafficking to the
TGN from the plasma membrane, and ATP7B has an F37AFDNVGYE45 sequence
involved in targeting to the apical membrane in polarized cells [47, 48].
In cultured cells, ATP7A and ATP7B localize to the TGN under basal con-
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ditions. When Cu level rises, ATP7A re-distributes to intracellular vesicles and/or
basolateral membranes, and protein expression is stabilized. In contrast, depending
on the cell type, ATP7B re-localizes to apical membrane or vesicles in the pres-
ence of high Cu [49]. ATP7B also undergoes a kinase-mediated phosphorylation
induced by Cu [50]. In the mouse intestine, ATP7A localizes to the TGN under
basal and dietary Cu-deficiency conditions, and traffics to vesicles near the baso-
lateral membrane after Cu administration. In the liver, ATP7A and ATP7B are
mainly expressed in hepatocytes. ATP7B expression can be found in the TGN and
intracellular vesicles, as well as the canalicular membrane [51].
In humans, ATP7A is ubiquitously expressed and required for dietary Cu ab-
sorption and peripheral tissue Cu transport. Dysfunction of ATP7A can lead to
Menkes disease in humans with poor Cu distribution in peripheral tissues (See Sec-
tion 1.3). ATP7B is highly expressed in the liver, and is involved in biliary Cu
excretion and Cu delivery to cuproenzymes such as ceruloplasmin [52]. ATP7B
expression also can be detected at lower levels in the brain, kidney, intestine and
placenta. Mutations in the ATP7B gene are associated with Wilson’s disease. Wil-
son’s patients exhibit overloaded Cu in the liver and brain that may lead to hepatic
disease, central nervous system dysfunction, and death. The administration of zinc
acetate to patients has been approved in order to induce the expression of Cu chap-
erone metallothionein (MT) and limit Cu absorption from the gut [53].
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1.1.3 Intracellular Cu distribution and storage
After being imported into cells by Ctr1, Cu(I) is transferred to several chap-
erone proteins and then delivered to Cu-dependent enzymes in various subcellular
compartments, such as the mitochondria and TGN. At the same time, several metal-
binding proteins can sense free cytosolic Cu levels and protect cells from toxicity
effects (Figure 1.2). The Cu chaperone for superoxide dismutase (CCS) is a Cu bind-
ing protein distributed in the cytosol and the mitochondria intermembrane space
(IMS) to mediate Cu transfer to Cu, Zn superoxide dismutase (SOD1). The pro-
duction of reactive oxygen species (ROS) such as hydroxyl radicals and superoxide
is intrinsically coupled with mitochondria respiration and these species are harmful
to cells. The reaction of Cu(I) with O2 in the mitochondria generates superoxide
and hydrogen peroxide (H2O2), and H2O2 may further react with Cu(I) to pro-
duce highly active hydroxyl radical [54]. SOD1 reduces cellular oxidative stress by
converting superoxide to less damaging H2O2 and O2 through the reduction and ox-
idation of Cu [55]. Deletion of CCS in yeast cells does not affect SOD1 abundance,
but interferes with Cu delivery to activate SOD1 functions, and thus CCS-null cells
are more susceptible to high levels of ROS [56]. CCS protein abundance is inversely
correlated with intracellular Cu levels, as Cu deficiency stabilizes CCS and elevated
Cu triggers its degradation through proteasome-mediated pathways. The Cys-X2-
Cys and Cys-X-Cys motifs in CCS domains I and III are responsible for Cu binding
to CCS, and domain II is involved in CCS docking to SOD1. In addition, Cu binding
to domain III is required for Cu-dependent CCS turnover: Cu binding alters the
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conformation of CCS and exposes a Lys residue for ubiquitination and degradation
[57, 58].
Cu chaperone antioxidant-1 (Atox1) is responsible for delivering cytosolic Cu
to ATP7A/B in the TGN and facilitating of Cu excretion. Atox1 localizes to the
cytosol and nucleus, and its distribution and abundance are not altered by Cu levels.
Atox1 physically interacts with ATP7A/B, and is required for ATP7A exiting from
the TGN under elevated Cu conditions. Atox1 contains a Cu binding motif that
shares high similarity with the fourth MBD of ATP7A/B (Met-X-Cys-X2-Cys).
Atox1 depletion in cells results in accumulated Cu levels and decreased cuproenzyme
activities, and Atox1-/- mice exhibit defects in systemic Cu delivery and die within
a few weeks after birth [59, 60]. In addition, Atox1 has been proposed to function
as a Cu-induced transcriptional factor to regulate cell proliferation [61].
Metallothionine (MT) is a small, cytosolic, Cys-rich protein that is capable
of binding several heavy metals, including copper, zinc, selenium and cadmium.
There are four MT isoforms in humans. MT1 and MT2 are highly expressed in the
intestine, liver and kidney, while MT3 and MT4 are enriched in the brain and skin.
Under Cu overload conditions, Cu binding to MT could protect cells from toxicity
[62]. Though MT-depleted mice exhibit normal growth and reproduction, they are
susceptible to heavy metal-induced oxidative stresses and inflammatory reagents
[63]. On the other hand, Cu stored by MT is vital for cells to survive under Cu-
limited conditions [64, 65]. In fruit flies and mice, elevated Cu induces the binding
of the trancription factor MTF-1 to the metal responsive elements (MREs) in the
promotor of the MT gene, and triggers MT gene expression [66]. Besides MT, Cu
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Figure 1.2: Cellular Cu metabolism in mammalian cells. Cu is imported as Cu(I) by
the Cu transporter Ctr1. Ctr2, the other CTR ortholog, facilitates Ctr1 truncation
and Cu export from endosomes. Once entering the cells, Cu(I) binds several chaper-
one proteins and is delivered to different subcellular destinations: CCS transfers Cu
to the Cu, Zn superoxide dismutase (SOD); Atox1 delivers Cu to the Cu exporter
ATP7A/B; and COX17 and other chaperones mediate Cu delivery to cytochrome
c oxidase in mitochondria. Cu can be stored by metallothionein and glutathione,






















can also be stored by glutathione (GSH). In GSH-depleted mammalian cells, a Ctr1
expression-independent reduction of Cu uptake was observed, suggesting a role for
GSH in handling Cu at the entry step [25, 67].
Cu delivery to the mitochondria is crucial for ATP biosynthesis. The Cu-
dependent enzyme cytochrome c oxidase (Cco) is the fourth enzyme complex in the
electron transport chain (ETC) required for the buildup of the electron gradient in
the IMS. The mitochondrial matrix contains a ligand-bound Cu pool that is nec-
essary for Cu incorporation into Cco. Thus, Cu needs to be transported from the
cytosol to the mitochondrial matrix and from the matrix to the IMS. The cytosolic
and mitochondria IMS-localized Cox17 (COX assembly factor 17) was hypothesized
to transport Cu from the cytosol to mitochondria. However, COX17 -depleted yeast
cells have normal mitochondrial Cu pool and normal Cco activity, suggesting alter-
native machinery for Cco Cu delivery [68, 69, 70]. To date, several Cu chaperones
are characterized for their function in this process, including Sco1, Sco2, Coa6,
Cox17, Cox11, Cox19 [71, 72, 73, 74, 75, 76]. The delivery of Cu from the mito-
chondrial inner membrane to the matrix is carried out by the phosphate transporter
SLC25A3 (yeast Pic2) [77], yet no transport mechanism is reported to deliver Cu
from the matrix to the IMS. In the IMS, Cox17 transfers Cu to Sco1 and Cox11.
Sco1 is crucial for incorporating Cu into the CuA site in Cco, facilitated by assembly
factors Sco2, Coa6 and Cox20. Meantime, Cox11 and several other Cco assembly
factors (Cox19, Cox23, Coa5) are responsible for CuB site metalation in the IMS
[78]. Human patients harboring mutations in SCO1, SCO2 or COA6 exhibit low
Cco activity and syndromes such as cardiac hypertrophy, hepatic failure, and en-
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cephalopathy. [79, 80, 81, 82]. Although Cu supplementation could rescue Cco
activity in patient-derived cells, it failed to alleviate major symptoms in human
patients [83].
1.1.4 Cuproenzymes and function
Here we describe several important Cu-dependent enzymes and their functions
in living organisms. Other cuproenzymes and functions are listed in Table 1.1 [84].
Tyrosinase is an oxidase involves in two catalytic steps during melanin synthesis.
It requires two Cu atoms in its active site in order to interact with dioxygen and
oxidize the substrate. Tyrosinase first oxidizes tyrosine to DOPA and then converts
the diphenol in DOPA to quinone. Dopaquinone can then be converted to dihyrox-
ylindole and then to melanin in the following reactions. In humans, tyrosinase is
highly expressed in the melanosomes of melanocytes in skin and eyes. Tyrosinase
dysfunction leads to low pigmentation and vision defects [85, 86].
Dopamine-β-hydroxylase (DBH) is required to convert dopamine to nore-
pinephrine (NE) in the central and peripheral nervous systems. Coupled with this
reaction, ascorbic acid and O2 are converted to dehydroascorbate and water, respec-
tively. NE is an essential neurotransmitter that participates in numerous physio-
logical pathways. It is involved in the regulation of heart rate and blood pressure,
glucose and lipid homeostasis, food digestion and renal reabsorption. Cu deficiency
in the brain results in low DBH activity and is correlated with several neuronal
disorders [87].
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Neurotransmitter norepinephrine generation from 
dopamine
Oxidase
Cytochrome c oxidase 
(CCO) Electron transport in mitochondria
Galactose oxidase Catalyzes the oxidation of D-galactose to D-galacto-hexodialdose in fungi
Amine oxidase Deamination of amines and form aldehyde and ammonia
Protein-lysine-6-oxidase
(lysyl oxidase)
Collagen and elastin cross-linking formation (one type 
of amine oxidase)
Superoxide dismutase Superoxide dismutation and antioxidant defense
Ceruloplasmin (Cp) Serum ferroxidase
Hephaestin Ferroxidase in the intestine
Ascorbate oxidase Acting on diphenol of L-ascorbate and convert to dehydroascorbate and H2O
Laccase Oxidize phenol groups of  lignin precursor in order to form cross-linking in plants and fungi
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Neuropeptides serve as signaling molecules for neuronal communication and
the regulation of brain activities. Maturation of more than half of neuropep-
tides to their active form requires amidation by the cuproenzyme peptidylgycine
α-amidating monooxygenase (PAM). Loss of PAM is embryonic lethal in mice
[88, 89]. PAM contains two functions domains, the peptidylglycine α-hydroxylating
monooxygenase (PHM), and the peptidyl-α-hydroxyglycine α-amidating lyase (PAL).
In order to be active, PHM must bind two Cu ions. First, PHM hydroxylates the car-
bon of the peptidylglycine, and then PAL catalyzes the cleavage of nitrogen-carbon
bond that generates the amidated peptide [90].
Ceruloplasmin and hephaestin are both Cu-containing ferroxidases. Cerulo-
plasmin is synthesized in the liver and requires six Cu ions delivered from ATP7B to
achieve oxidase function. Ceruloplasmin is primarily a soluble serum oxidase, and
ferric ions oxidized by ceruloplasmin can bind transferrin in the blood and then be
mobilized to other tissues. Hephaestin is a transmembrane protein expressed in the
small intestine required for dietary iron absorption. It functions together with the
iron transporter ferroportin in the basolateral membrane of enterocytes to mobilize
iron exported from the intestine to circulatory system [91, 92]. Cu deprivation in
the intestine would decrease hephaestin activity and lead to systemic iron deficiency.
Lysyl oxidase (LOX) is involved in generating collagen and elastin cross-linking
by catalyzing the formation of aldehydes from lysine residues. Cu binding to apo-
LOX triggers electron transfer and deamination of lysyl groups in collagen and
elastin precursors. Formation of cross-linking is essential to stabilize these fibrils
and support tissue structures [93, 94].
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1.2 Mammalian Cu homeostasis at the organismal level
1.2.1 Dietary Cu uptake and transport into circulation
The intestinal epithelium is the main site for dietary Cu absorption, and the
daily Cu uptake amount ranges 0.6-2.4 mg on average in adult humans [95]. Dietary
Cu(II) is reduced, and Cu(I) is imported into enterocytes via Ctr1 localized to the
apical membrane. Cu then binds to chaperone proteins and is either targeted to dif-
ferent subcellular destinations, exported, or being stored, as described above. Under
Cu adequate conditions, biotin-labeled Ctr1 localized to both the apical surface and
intracellular vesicles in the mouse intestine. Ctr1 was localized mainly on the apical
membrane when mice were fed with Cu-deficient diet [36]. The expression of Ctr1
is also age-dependent, as infant mice express higher levels of Ctr1 protein compared
to adults. This is in accordance with a decrease in systemic Cu levels over time
[96]. In mice fed a standard diet, ATP7A localizes primarily to the TGN. After an
increase in dietary Cu uptake, ATP7A re-localizes to vesicles close to the basolateral
side of enterocytes in order to mediate Cu efflux to the portal circulation [97]. No
age-dependent expression regulation has been observed for ATP7A.
Cu in the circulatory system likely binds to ligands in order to be transported
to peripheral tissues, as free Cu is oxidative active and harmful. It has been sug-
gested that up to 95 % of Cu in the circulation is bound to ceruloplasmin (Cp)
for peripheral delivery. However, Cp-depleted mice exhibit normal tissue Cu distri-
bution [98]. Albumin and macroglobulin may also bind Cu with lower affinity in
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the blood stream, but have been demonstrated not essential for systemic Cu trans-
portation, suggesting an alternative but yet unknown mechanism of Cu circulation
[99, 100].
1.2.2 Hepatic Cu storage and excretion
Liver is the primary organ for Cu storage and regulation of systemic Cu home-
ostasis. After export from the intestine, Cu in the circulation is imported into liver
by hepatic Ctr1 [96]. When administering high doses of Cu to mice through sub-
cutaneous injection, the increased Cu predominantly accumulates in the liver, with
little change of Cu levels in other tissues such as heart, brain or serum. The ex-
pression of hepatic Ctr1 is induced simultaneously, indicating Cu uptake through
hepatic Ctr1 is responsible for systemic Cu detoxification [101].
Cu stored in the liver can be mobilized to peripheral tissues, transferred into
cuproenzymes such as Cp, or excreted into the bile if present in excess. ATP7A
is presumably required for exporting Cu from the liver to peripheral tissues, as
suggested by elevated hepatic ATP7A expression together with increased serum Cu
in the cardiac-specific Ctr1 knockout newborn mice [102]. The function of hepatic
ATP7A may be vital during the early postnatal stage, as ATP7A protein abundance
decreases from newborn to adulthood. This is in accordance with the total Cu stored
in the liver, which remains high around birth and is gradually reduced over the
course of life span [103, 104]. Future studies are required to elucidate the functions
of liver ATP7A. Excess Cu in the liver is excreted into bile by ATP7B. Elevated
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Cu in hepatocytes induces ATP7B trafficking from the TGN to vesicles close to the
apical surface for Cu excretion [105, 106, 107]. Notably, COMMD1 (Cu metabolism
Murr1 domain 1) is required to stabilize hepatic ATP7B protein and to maintain
its proper function [108].
1.2.3 Cu metabolism in heart, kidney and brain
Kidneys balance nutrient homeostasis in the circulation via nutrient filtration
from the blood into primary urine and via reabsorption into renal tubules. Little is
known regarding Cu trafficking and regulation in the kidney. Urinary Cu levels are
highly induced if biliary Cu excretion is blocked or decreased in ATP7B-/- mice and
by hepatic Ctr1 deletion. These observations suggest an active role for the kidney in
regulating systemic Cu homeostasis [109, 110]. Ctr1 is expressed in both proximal
and distal tubules and may import Cu from primary urine back to renal cells. This
is supported by elevated Ctr1 expression levels in dietary Cu-deficient mice [96].
ATP7A and ATP7B are both expressed in renal tubules, and ATP7A localizes to
the basolateral membrane under high Cu conditions, indicating a possible function
in exporting Cu from renal cells back into the blood [111].
Relative to other organs, cardiac tissue contains a large amount of mitochon-
dria and is in high demand of Cu to maintain proper mitochondrial function for
contraction. Dietary Cu deficient animals exhibit cardiac hypertrophy and abnor-
mal mitochondrial morphology and function, which can be rescued by supplementing
Cu back through the diet [112, 113, 114]. In addition, cardiac-specific Ctr1 deple-
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tion in mice resulted in low Cu and cuproenzyme levels in the heart, cardiac Cu
hypertrophy, and failure to survive beyond two weeks after birth [102]. Though car-
diac hypertrophy can be caused by exercises and pregnancy, prolonged hypertrophy
may lead to cardiac dysfunction and heart failure [115, 116].
The brain requires a steady amount of Cu for neurological development and
proper functions during peptides maturation and neurotransmitter production through
Cu-dependent enzymes as described above. Meanwhile, Cu overload in the brain
could result in neurodegeneration and other disorders. In the brain, Ctr1 is local-
ized to the apical membrane of choroid plexus cells and endothelial capillaries. The
expression of Ctr1 can be induced by Cu deficiency, indicating a role for Ctr1 in
facilitating Cu uptake from cerebrospinal fluid. ATP7/B is expressed in most brain
regions, and similar to other tissues, ATP7A/B expression levels in the brain are
also age-dependent [117, 118]. How neuronal Cu is being stored and utilized, and
how Cu metabolism is regulated in the brain will need to be elucidated in the future.
1.2.4 Cu homeostasis in C. elegans
Caenorhabditis elegans (C. elegans) is a genetically tractable, multi-tissue or-
ganism that has been proven to be amenable to nutrient absorption and distribu-
tion studies using zinc, iron and heme [119, 120, 121, 122]. Several orthologs of
Cu binding proteins have been identified in worms by sequence homology studies,
including CUA-1 (ortholog of ATP7A/B), CUC-1 (Atox1), MTL-1/2 (MT), GCS-
1(GSH), SCO-1(Sco1/2), SOD-1(Sod1), COX-17(Cox17), TYR-1-6 (Tyrosinase),
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CCO-1(Cco), TBH-1(DBH), as well as putative orthologs for PAM and SLC25A3.
Interestingly, no CCS ortholog has yet been identified in worms. The activation
of C. elegans Cu, Zn-Sod can be achieved in the absence of CCS, but potentially
requires GSH for proper activity [123].
Among the components that are required for Cu trafficking, the functions of
metallothionein, as well as CUC-1 and CUA-1 have been delineated in C. elegans
[124, 125]. Expressing the cua-1 gene could complement the function of yeast Cu
exporter by rescuing the growth defect of ccc2∆ cells. In C. elegans, cua-1 is ex-
pressed in the intestine, hypodermis, pharynx and neurons. Depletion of cua-1
causes lethality under Cu deficient conditions that can be rescued by Cu supple-
mentation. Intestinal CUA-1 localizes to the basolateral membrane under basal and
Cu-deficient conditions, and traffics to gut granules upon dietary Cu supplementa-
tion or Cu injection to the pseudocoelom. This trafficking likely functions to protect
peripheral tissues from Cu toxicity. In addition, hypodermal cua-1 transcription can
be induced by Cu deficiency. These findings suggest CUA-1 as a key intestinal Cu
exporter responsible for maintaining systemic Cu homeostasis [126, 127, 128]. How-
ever, mechanisms by which the C. elegans intestine acquires Cu have yet to be
characterized.
C. elegans metallothioneins mtl-1/2 are expressed in the intestine, and the ex-
pression of both genes can be induced by the heavy metal cadmium (Cd). Despite
the fact that mtl-1/2 -depleted worms are highly susceptible towards several heavy
metals, high concentrations of Cu or Zn are not able to increase mtl-1/2 expres-
sion in C. elegans. MTL-1 and MTL-2 have different affinities towards Cd and Zn,
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suggesting distinct roles of two MT isoforms in worms. In addition, the promoter
of mtl-2 contains a TATAA box and a MRE sequence and requires the transcrip-
tion factor ELT-2 to initiate the expression [129, 130, 131, 132]. However, because
no MTF-1 or Mac1 homologs have been identified in C. elegans, the metal-sensing
transcriptional regulators for MTs remains elusive. Worms may adapt unique mech-
anisms for heavy metal-induced transcriptional regulation [133, 134].
1.3 The anti-cancer drug elesclomol in Cu homeostasis
1.3.1 Elesclomol-Cu(II) as cancer therapy
Elesclomol (STA-4783) is a synthesized chemical compound with the formula
of N-malonyl-bis (N'-methyl- N'- thiobenzoylhydrazide). It was originally derived
from a screen for molecules with potent proapoptotic activity and has become a
first-in-class anti-cancer drug. Elesclomol induces mitochondria oxidative stress by
generating reactive oxygen species (ROS) in cancer cells through its interaction with
copper [135, 136, 137]. Since 2004, several phase I-III studies have been conducted
using elesclomol, with regards to its efficacy in treating several types of cancers, such
as metastatic melanoma, prostate cancer, ovarian epithelial cancer, solid tumor,
myeloid leukemia, etc. [138, 139, 140].
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1.3.1.1 Elesclomol achieves cytotoxicity through its interaction with
copper
Cancer progression is often coupled with increased demand for nutrient and
energy. With sufficient energy supplementation, cancer cells tend to become hy-
poxic, invasive, and relatively resistant to treatments like radiation and chemother-
apy. During cancer development, the mitochondria plays a vital role: it is not only
responsible for energy production, but also participates in ion homeostasis, pro-
grammed cell death, and oxidative stress regulation. Cancer cells commonly exhibit
altered mitochondrial morphology and redox status, with increased levels of reac-
tive oxygen species [141, 142, 143, 144]. Interestingly, the build-up of ROS could
further stimulate oncogenic pathways that favor cell proliferation. However, on the
contrary, high ROS levels in cancer cells result in a lower antioxidant capacity. This
provides a potential therapeutic strategy by providing high levels of oxidative stress
to cancer cells that exceed the threshold for cells to survive. Because normal cells
maintain low levels of ROS, they are less susceptible than cancer cells, as long as the
oxidative stress inducer is administrated at the correct dose. This is supported by
several studies, demonstrating increased cellular ROS levels could effectively erase
cancer cells in vitro. Meanwhile, at similar doses, elesclomol showed little to no
impact on normal cells [145, 146, 147].
As one of the ROS-inducing drugs, ES administration to a variety of mam-
malian cancerous cells in culture induces the expression of stress responsive genes
including several heat shock proteins, and cell survival proteins and metallothionein.
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Meanwhile, within a few hours of administration, cells accumulate high levels of
ROS, followed by increased expression of apoptotic genes, reduced mitochondrial
membrane potential and leakage of mitochondrial components to into the cytosol
[148, 149]. Studies further revealed the interaction with Cu(II) is required for ES
cytotoxicity effects [150, 151].
Among metal ions that are able to form complexes with elesclomol, Cu(II) is
strongly preferred over zinc, iron, or manganese in competition assays. Cu binds to
elesclomol at a 1:1 ratio; the coordination between Cu, sulfur, and nitrogen atoms
changes elesclomol to a flat structure and yields a highly hydrophobic molecule,
enabling the complex to penetrate cell membranes [152]. The complex is highly
stable, as a competition assay at pH 7.4 suggested a 24-fold stronger binding of ES-
Cu(II) compared with TRIEN-Cu(II), the latter of which has a stability constant of
10-20 M [153, 154, 155]. Although elesclomol could also bind platinum and nickel to
form cell membrane-permeable complexes, the elesclomol-Cu(II) complex exhibits
much higher cytotoxicity than complexes with Ni(II) or Pt(II), possibly due to the
low redox potential of Ni(II) or Pt(II) complex [154]. Under Cu-deprived conditions,
elesclomol failed to enter cells or induce apoptosis in cultured cancer cells, suggesting
that the drug must enters cells as an ES-Cu(II) complex.
Upon entering cells, the ES-Cu(II) complex preferentially delivers Cu to mi-
tochondria. Cu is then disassociated while ES is shuttled outside of the cell. This is
supported by the highly increased radiolabeled Cu levels and less accumulation of
ES in the cell shortly after drug administration. Approximately 80% of ES-bound
Cu was found in mitochondria, around 14% was distributed in the cytosol and 6% in
23
the nucleus [156]. The selective accumulation of ES-bound Cu in the mitochondria
is unique, and likely accounts for its cytotoxic effect. When compared to another
Cu chelator that also induces oxidative stress, disulfiram (DSF), DSF-Cu is mainly
retained in the cytosol and exhibits weaker potency in triggering apoptosis than
ES-Cu [157, 158, 159]. To date, it is not yet clear how ES-Cu selectively targets the
mitochondria.
A comprehensive screen of the yeast deletion collection suggests that ES does
not target any specific protein in the cytosol [160, 161]. Nonetheless, yeast with
homozygous gene deletions related to electron transport, cytochrome assembly and
Cu-related functions revealed high sensitivity to ES administration. Another ob-
servation noted that ES-Cu(II) in mitochondria can be quickly reduced to Cu(I),
accompanied by the generation of ROS and followed by mitochondria apoptosis in
cancer cells [156]. Interestingly, the redox potential of Cu(II) to Cu(I) matches the
potential drops in electron transport chain (ETC), suggesting the association be-
tween Cu redox and electron transport in mitochondria [23]. Taken together, these
findings suggest the possibility that ES-Cu(II): 1) generates ROS through the redox
property of Cu after Cu(II) disassociates from ES, perhaps utilizing electrons and
redox potential in the ETC; 2) relies on the interaction with ETC components to
release Cu(I) from ES, leading to the release of free radicals during the reaction; 3)
the possibility that 1) and 2) can take place together to trigger apoptosis. Further
studies are required to elucidate this mechanism.
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1.3.1.2 Clinical study of elesclomol in cancer treatment: progress and
limitations
Elesclomol has been tested with hundreds of cancer or cancer-derived cell lines
and revealed to potently kill almost all cancer cell types in vitro, with IC50 below
100 nM (results available online from Sanger Institute). Unlike most other Cu-based
anti-cancer drugs, little to no toxicity effect was observed in normal cells.
Human clinical studies involving elesclomol were launched in 2004. Several
Phase I and II studies demonstrated improvements in progression-free survival and
risk reduction for the disease in patients suffered from myeloid leukemia, refractory
solid tumors, peritoneal cancer, and stage IV metastatic melanoma, after several
weeks of ES administration [138, 139, 140, 162, 163, 164]. ES was often admin-
istrated together with Paclitaxel, an anti-cancer drug targeting the disruption of
microtubules, and the efficacy of which positively correlated with cellular ROS lev-
els [165]. By elevating the oxidative stress, ES may improve the overall efficacy of
Paclitaxel when treated in a combination.
Combined results from Phase II and III trials suggested that the therapeutic
benefit of ES, however, only applied to a subset of patients. This subset can be
distinguished by patients′ serum lactate dehydrogenase (LDH) levels. LDH is a
cancer prognosis marker, and the levels of LDH in the bloodstream correlate with
tumor hypoxia state and metabolism type. Hypoxic cancer cells tend to utilize
glycolysis rather than oxidative phosphorylation for metabolism, resulting in high
LDH levels in cytosol and circulation. On the contrary, ES mainly targets the
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ETC in mitochondria; it may be more active in oxygenated cells with metabolically
active mitochondria. This may explain why ES revealed efficacy only in patients
with normal serum LDH [166]. In a randomized, double-blinded phase III study of
elesclomol for stage IV metastatic melanoma on 651 patients, the combination of
ES and Paclitaxel failed to see a significant improvement in progression-free survival
when compared to Paclitaxel alone. This study was terminated later in 2014 [167].
Researchers are now looking for novel therapeutic strategies in parallel with ES
administration [168, 169, 170, 171].
1.3.2 Elesclomol rescues mitochondrial function in copper-deficient
models
1.3.2.1 Copper is required for mitochondria energy production
Cu is required for the assembly and activity of cytochrome c oxidase (Cco),
the fourth enzyme complex of the ETC. Cco localizes to the mitochondrial inner
membrane and is responsible for the reduction of the final electron acceptor oxy-
gen during energy production. Cco consists of 14 subunits, among which Cox1 and
Cox2 contain two Cu-binding sites, CuB and CuA, respectively. The CuA site ac-
cepts electrons from reduced cytochrome c, and CuB-heme a3 is the site for oxygen
reduction [172, 173]. Because Cox1 and Cox2 are expressed and assembled inside of
mitochondria, Cu must be delivered from cytosol. Cu is thought to be stored in the
mitochondrial matrix as a ligand-bound form and utilized as the major Cu source
for Cco assembly in the IMS [70, 174]. Cu deficiency in the mitochondria disrupts
26
Cco assembly and results in respiratory defects.
1.3.2.2 Elesclomol administration restores mitochondrial function in
genetic models of Cu deficiency
In a study conducted by S. Soma et al., elesclomol stood out from several
other copper-binding small molecules, and rescued Cco activity and mitochondrial
Cu levels in coa6 - and sco2 -depleted yeast [175]. Unlike in cancer-related studies, the
dosage of elesclomol used in this Cu-deficiency rescue study was carefully monitored
to avoid over-production of oxidative stress and cytotoxicity. ES could also rescue
the respiratory growth defect in yeast harboring mutations in the Cu transporters
ctr1, ccc2, and Cu chaperones ccs1 and atx1. In cultured cells, ES significantly
rescued COX1 levels in Ctr1 -depleted cardiomyocytes as well as in SCO2 patient
cells. Moreover, ES supplementation rescued low Cu-related phenotypes in both
Ctr1- and Coa6- depleted zebrafish.
Given the fact that ES preferentially delivers Cu to mitochondria, it is exciting
to observe the rescue phenotype by ES in ccs1 - and atx1 - mutant cells, suggesting
that ES could potentially deliver sufficient amounts of Cu to cytosolic SOD and
to the secretary pathway to rescue Cu-deficiency related disorders. This study
shed light on the novel application of ES in treating cellular and mitochondria
Cu deficiency disorders, and encouraged further studies in mammals using genetic
Cu-deficient models and clinical-related models.
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1.3.3 Copper deficiency-related genetic mouse models
While dietary-Cu deficient mice provided insights into systemic responses upon
Cu depletion, genetic models are powerful tools for revealing functions of certain
genes, discovering mechanisms of systemic Cu homeostasis, and characterizing ther-
apeutic hypotheses. Mouse strains containing mutations in the two major Cu trans-
porters, Ctr1 and ATP7A are available. Whole body knockout of either Ctr1 or
ATP7A is embryonic lethal, suggesting normal Cu homeostasis is crucial for embry-
onic development [40, 176, 177]. This section describes Ctr1 tissue-specific knockout
models and disease-related ATP7A mutant mouse models.
1.3.3.1 Tissue-specific Ctr1 depleted mouse models
The role of Ctr1 in intestinal Cu absorption has been characterized using the
intestinal Ctr1 knockout mouse model (Ctr1int/int). These mice exhibited poor Cu
distribution in peripheral tissues and defects in growth and viability (with a median
survival of 15 days). Cco and other Cu-dependent enzymes’ activity were signifi-
cantly reduced in the majority of peripheral tissues. Interestingly, the intestine of
Ctr1int/int mice accumulated high levels of non-bioavailable Cu. Other pronounced
findings include cardiac hypertrophy and accumulated iron in the liver. These de-
fects could be rescued by Cu-histidine administration at the early postnatal stage.
The Ctr1int/int mice is a useful model to study dietary and peripheral Cu-deficiency
[41].
The cardiac-specific Ctr1 depleted mouse (Ctr1hrt/hrt) provides a novel aspect
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towards understanding systemic Cu homeostasis regulation. Ctr1hrt/hrt mice exhibit
low heart Cu levels, reduced Cco activity and cardiac hypertrophy, and the me-
dian survival for these mice is 10 days. Cu storage levels in the livers are decreased,
coupled with increased serum Cu levels, and hepatic ATP7A protein levels are upreg-
ulated. In addition, treatment with Ctr1hrt/hrt mice serum induces ATP7A protein
expression in cultured cells. These findings strongly suggest a potential systemic sig-
naling communicating between the liver and heart to regulate Cu homeostasis [102].
This model has provided useful insights for several following studies to characterize
to understand the function of Sco1 in heart [37, 178].
1.3.3.2 Menkes disease
Introduction to Menkes disease and mottled mice
Menkes disease (MNK) is a recessive disorder caused by mutations in the gene
encoding the Cu transporter ATP7A, resulting in poor intestinal Cu absorption,
poor renal reabsorption, inability of Cu to cross the blood-brain-barrier (BBB),
and dysfunction of most cuproenzymes [107, 179, 180], including tyrosinase, lysyl
oxidase, dopamine-β-hydroxylase and peptidyl-α-amidating monooxygenase. The
incidence of Menkes disease ranges from 1 in 100,000 to 1 in 250,000 newborns.
Symptoms of Menkes disease includes kinky hair, growth retardation, hypothermia,
weak muscle tone, hypo-pigmentation, low serum ceruloplasmin levels and intellec-
tual disability [181]. The majority of Menkes children die within three years if not
given any treatment.
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ATP7A protein is highly conserved among animals. It is a membrane protein
consisting of eight transmembrane domains, an ATP binding domain, a cytosolic
N- terminus containing six Cu-binding motifs, and several other conserved motifs
required for proper ATPase function. In cultured cells, ATP7A traffics to the plasma
membrane for Cu efflux under Cu sufficient conditions, and is localized to the trans-
Golgi network (TGN) in the absence of Cu. TGN-localized ATP7A could deliver Cu
to cuproenzymes in the secretary pathway. Thus far, around 370 ATP7A mutations
have been identified in humans [6, 182]. The major types of mutations found in
Menkes patients include missense mutations, splice site mutations, exon deletions,
small deletions and nonsense mutations in ATP7A [183].
Mice carrying mutations in the Atp7a gene are named mottled mice, due to the
lack of their coating pigmentation. So far, 109 mottled alleles have been identified: 24
resulted from spontaneous mutations, while others were generated by gene trapping,
chemical induction or targeted mutagenesis [184]; so far 15 mottled mouse strains
have been characterized. Among these strains, 8 are embryonic lethal, suggesting an
important role of ATP7A for prenatal development. Macular, mosaic and brindled
mutations are postnatal lethal around two weeks old. These strains share many
common phenotypic features with human Menkes disease and serve as powerful
tools for early postnatal therapeutic studies [185].
Current therapeutic strategies and challenges
Cu injection is the most common treatment for infant Menkes patients. The
daily injections have been shown to partially improve clinical symptoms and prevent
lethality only if Cu-histidine is introduced shortly after birth. This therapy results
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in poor outcomes, however, if infants harbor loss-of-function ATP7A mutations or
if they started treatment after two months of age, because the mature blood-brain-
barrier prevents Cu from entering neurons [186, 187, 188]. The Cu administered
during this treatment also failed to be effectively transported into the TGN to
rescue connective tissue abnormalities and other cuproenzyme-related symptoms. In
utero Cu treatment also revealed similar limitations for babies with severe ATP7A
mutations [189].
Gene therapy studies have been conducted with mottled-brindled mice by in-
troducing ectopic ATP7A to the mouse brain. Menkes mice receiving adenoviral-
ATP7A plus Cu-histidine injections to the lateral cerebral ventricle had an extended
lifespan (median survival was 43 days compared to mottled-brindled mice median
of 16 days), increased brain Cu levels, and enhanced dopamine-β-hydroxylase activ-
ity [190]. Recently, the same group of researchers introduced rAAV9-rsATP7A to
the cerebrospinal fluid in addition to subcutaneous Cu administration to mottled-
brindled mice. This strategy improved median lifespan from 16 days to 300 days,
with normal growth and development, significantly improved brain neurochemical
levels, Cco activity and neurobehavior. Clinical research is expected soon with this
method [191].
Chemotherapy that uses oral disulfiram administration together with Cu-
histidine injection has been characterized with macular mice and in a limited number
of patients. Compared to macular mice or mice with Cu injection only, this method
significantly enhanced Cu delivery to the brain, serum and liver, and reduced excess
Cu accumulation in kidney. Dopamine-β-hydroxylase had a slight increase of activ-
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ity in the brain, indicated by the ratios of noradrenaline and adrenaline to dopamine
in cerebral fluid [192, 193, 194]. For Menkes patients, this method was inconsistently
effective at improving neurological symptoms and at elevating cerebral Cu levels,
and dopamine-β-hydroxylase activity was not altered after the treatment in all cases
[195].
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Chapter 2: Materials and Methods
2.1 C. elegans experimental procedures
Worms Strains and Culture
C. elegans were cultured at 20°C on nematode growth medium (NGM) plates
seeded with E. coli OP50 for general maintenance or with E. coli HT115 dsRNA-
expressing bacteria for RNAi experiments [196]. Bristol N2 was used as the wild-type
C. elegans strain. Mutant and transgenic strains were outcrossed with N2 to ob-
tain wild-type backgrounds, and a wild-type brood mate animal was used following
crossing in mutant and transgenic animal growth/avoidance assays. Some strains
were provided by the CGC, which is funded by NIH Office of Research Infrastruc-
ture Programs (P40 OD010440). The chca-1 (tm6506) IV strain was obtained from
the National Bioresource Project [197] and outcrossed with N2 six times prior to
use to establish heritability; CB1033 (che-2 (e1033) X) was obtained from CGC
and outcrossed six times before use for the same purpose. A list of transgenic
worms used in this study can be found in Appendix Table 2. Transgenic animals
in a chca-1 (tm6506) mutant background, as well as multiple transgene-presenting
strains, were generated with standard mating methods; genotypes were confirmed
by PCR and/or DNA sequencing. The chca-1(tm6506) genotyping primers were: 5'-
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GTATCTAGTCCGATAAGAAG -3' and 5'-TTGAAGCAAAAACAAAGTGC-3'.
RNA Interference (RNAi)
HT115 (DE3) bacterial strains containing plasmids expressing dsRNA against
F27C1.2, F31E8.4, Y58A7A.1, F58G6.7, F58G6.9, K12C11.6, and K12C11.7 genes
were obtained from the Ahringer and ORFeome feeding libraries [198, 199]. The
empty vector L4440 was used as a control. Portions of F01G12.1, K12C11.3,
and F58G6.3 DNA constructs were cloned into the L4440 vector and transformed
into HT115 bacteria. Each construct was sequenced using the primer 5'- AGC-
GAGTCAGTGAGCGAG -3', and evaluated by the E-RNAi online tool (e-rnai.org)
to determine the RNAi target. NGM growth media with 12 µg/mL of tetracycline,
50 µg/mL carbenicillin, and 2 mM IPTG (isopropyl 1-thio-β-D-galactopyranoside)
was used for RNAi experiments.
BLAST and Topology Prediction
The human CTR1 protein sequence was used as a query sequence in a search
using PSI-BLAST. Non-redundant protein sequences (nr) were chosen for the database,
and results were filtered to include only hits on the Caenorhabditis elegans (taxid:6239)
genome. Candidates had an E-value cut-off of less than 10−3. TMD of various or-
ganisms’ CTR homologs were predicted by TMHMM 1.0. Clustal Omega was used
to generate sequence alignment.
Axenic Media Growth
The axenic liquid media used in this study (“low Cu” mCeHR) is modified from
the mCeHR media described previously [119] by removing extra Cu supplementation
in the salt solution. 20 µM hemin was added for every culture condition. N2 worms
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grown in “low Cu” mCeHR media were synchronized and hatched overnight in M9
buffer. Approximately 100 L1 stage worms were seeded into a 10 mL liquid media-
containing flask with indicated CuCl2 or BCS concentrations. Flasks were incubated
on a rotating platform at 20 °C for 9 days. On day 9, animals were collected, samples
were centrifuged (800 xg, 1 min) to collect the worm pellet, and then washed twice
with M9 buffer. To count the number of worms, the tube was vortexed to mix, a
prescribed amount of sample was drawn up and placed on a slide, and worm counts
were calculated. Each condition was tested and counted in triplicate.
qRT-PCR
For assays conducted in axenic media, N2 worms were maintained in 10 µM
CuCl2 “low Cu” mCeHR, and then synchronized and split into flasks containing
10 µM CuCl2 (optimal), 300 µM CuCl2 (high Cu), or 100 µM BCS (low Cu) me-
dia. Worms were grown in each condition until the population reached the mid-L4
stage. Worms were collected after washing twice with M9 buffer and resuspended
in 1 ml Trizol (Invitrogen), then lysed in Lysing Matrix Tubes (MP Biomedicals)
using a FastPrep-24 (MP Biomedicals) homogenizer. Total RNA was isolated using
the NucleoSpin RNA kit (Macherey-Nagel), and 1 µg RNA was used for cDNA syn-
thesis (SuperScript III First Strand synthesis kit, Invitrogen). Real-time PCR was
performed with SYBR Green Taq 2x Mix (BioRad) with three biological replicates
and two technical replicates. Fold change values were calculated using the 2(-∆∆Ct)
method, with all values normalized to pmp-3 or gpd-2 expression. Primers are listed
in Appendix Table I.
Quantification of Cu-dependent Worm Growth, Length, Brood Size,
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and Cu Levels
Assays were performed as follows, unless specified in figure legends. For worm
growth assays and length quantification, stage-synchronized L1 worms (P0) were
grown on RNAi-expressing bacteria until vector-fed control worms reached the L4
stage. P0 worms were washed off the culture media with M9 buffer and 100 µL
of worms in M9 buffer was transferred into a 96-well culture dish. Animals'body
length (TOF), density (extinction), and fluorescence intensity were quantified using
a COPAS Biosort system FP-250 (Union Biometrica). To perform these assays on
F1 worms, 20 P0 worms were transferred to fresh plates at the L4 stage and allowed
to lay eggs for 12 h after reaching the gravid adult stage. P0 worms were removed
from the plate, and F1 progeny were analyzed as above upon reaching the L4 stage.
For brood size analysis, synchronized L1 worms were cultured on dsRNA-
expressing bacteria for 50 h until reaching gravid adult stage. Individual worms
were then transferred onto fresh plates to allow egg-laying. After 3 consecutive days
of egg-laying, the brood size, including both hatched and unhatched embryos was
counted.
For Cu-pulse experiments, a mixed stage population was cultured on BCS-
supplemented NGM plates for 5 days prior to synchronization. BCS-treated worms
were then bleached to generate synchronized L1 animals which were then cultured
on BCS plates for 48 h, washed off, and split evenly onto BCS- and Cu-supplemented
plates for 12 h prior to worm pelleting. Restored Cu levels for each experimental




Metal contents of worms were measured using ICP-MS as described previously
[41]. Values were normalized to wet weight of worms. For sample preparation,
synchronized L1 worms were grown on NGM plates seeded with OP50 or HT115
RNAi bacteria and supplemented with the indicated amounts of copper or BCS until
worms reached L4 stage. Worm pellets were collected and washed extensively with
M9 buffer, transferred to acid-washed tubes, and frozen at -80 °C. At least three
independent biological replicates were analyzed.
Generation of Transgenic Worms
Transgene-expressing plasmids were generated using a Multisite Gateway Three-
Fragment Vector Construction kit (Invitrogen). Promoter, ORF, and UTR regions
were amplified separately and recombined into the plasmid. The unc-54 3'UTR
region is used in all constructs in this study. Together with the unc-119 rescue plas-
mid, the transgene-expressing plasmid was then introduced into unc-119 (ed3) III
worms using a PDS-1000 particle delivery system (Bio-Rad) bombardment system.
To generate worm strains expressing multiple transgenes, one worm strain express-
ing a single transgene was crossed with another transgenic worm using methods
previously described [200]. All transgenic worm strains used in this study are listed
in Appendix Table II.
Staining with the Cu Probe CF4
Stage-synchronized L4 worms expressing CHCA-1::GFP in the intestine were
used for the CF4 assay. Worms were washed three times with M9 buffer, and
around 400 worms were suspended in 100 µL M9 buffer. CF4 Cu probe [126] was
37
then added to the buffer at a concentration of 25 µM. Worms were stained in the
dark at room temperature for 2 h, and then transferred on normal NGM plates
outside the bacterial lawn. These plates were kept in the dark for 2 h, and then
the worms were collected and washed three times with M9 buffer and imaged via
confocal microscopy.
Cu-responsive Behavior Assay
The Cu-avoidance assay in this study utilized rectangular Cu gradient plates.
To make Cu gradient media, 4-well rectangular plates were tilted on their lids and
2 mL Cu-containing media (with indicated concentrations of CuCl2 in 1.7 % agar,
3 mg/mL NaCl, 5 µg/mL cholesterol, and 2.5 mg/mL bacto-peptone) was added to
one third of the plate length. Upon solidification, plates were brought flat and 10
mL NGM agar was added on top. For control experiments with non-Cu containing
plates, plates received 12 mL of NGM agar alone. After upper layer solidification,
plates were kept at 4°C for 16 h to allow Cu diffusion prior to conducting the
assay. Five sections were drawn on the bottom of the plates (indicating low to high
Cu) for future quantification of worms per section as delineated by approximate
concentration. Synchronized L4 worms were washed three times with M9 solution
to remove bacteria, and 40 µL of worm-M9 solution was pipetted in the middle
section of the plate (section three). Following a 2.5 h drying period, images of the
plates were captured by camera and animals in each section were counted using
Image J software. Each assay included at least 150 animals, and at least three
independent experiments were performed for each condition. Avoidance behavior of
the high Cu regions (sections four and five) were denoted by an Avoidance Index
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(AI) derived from the following formula:
Avoidance Index(AI) = Percentage of worms in section [(4+5)–(1+2)]Percentage of worms in section [(4 + 5) + (1 + 2)]
Worms in section three were not calculated, as not all worms translocated to
different sections in the given time frame.
Immunofluorescence and Western Blot
The antibodies applied in the worm immunofluorescence assays are rabbit anti-
FLAG (Rockland) at 1:300, and Alexa594 goat anti-rabbit IgG (ThermoFisher) at
1:300. For each condition, 75 µg of protein was loaded into gels. Transgenic animals
expressing CHCA-1-2xFLAG::SL2::GFP in the intestine were stage-synchronized
and L4 worms were fixed and stained with antibody as previously described [201].
Worms stained with secondary antibody only served as negative controls.
C. elegans treatment with elesclomol
WT worms (Bristol N2), BK015 (Pvha-6 ::CUA-1.1::GFP::unc-54 3'UTR; cua-
1(ok904)) worms, chca-1 (tm6506 IV ) and the wild-type brood mate (WT) worms
were maintained at 20 °C on nematode growth medium (NGM) plates seeded with
E. coli OP50 or HT115 (DE3). For brood size counting, N2 worms were exposed to
cua-1 or control (L4440 vector) RNAi from synchronized L1 stage with or without
100 µM BCS treatment, supplemented with vehicle (DMSO) or 5 µM ES. After
4 days, worms under each condition were picked to individual plates in triplicate,
allowed to lay eggs, and transferred to fresh plates every 24 h for 3 days. Eggs were
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incubated overnight to allow hatching and progeny number was determined as the
total hatched larvae. For the survival assay, BK015 transgenic worms were cultured
on RNAi plates supplemented with either vehicle (DMSO) or 5 µM ES from the L1
stage for 4 days, and then score for survival. Animals were considered dead when
no signs of viability (movement, pharyngeal pumping, or response to prodding)
were detected. WT and tm6506 worms were cultured using basal media or media
containing 100 µM BCS conditions plus 10 µM CuCl2 or various concentrations
of ES. Worms were collected at young adult stage for ICP-MS analysis or for size
quantification.
2.2 Yeast experiments
Yeast Strain and Spotting Assay
The MPY17 Saccharomyces cerevisiae strains used in this study contained
a scCTR1 and scCTR3 double deletion [18]. Genes were tagged at the carboxyl
terminals with a 2x FLAG sequence and inserted into a pYES3 vector [202]. Plas-
mids containing either FLAG gene insertions or FLAG tag only were transformed
into CTR1∆CTR3∆ yeast. Yeast strains were maintained in a synthetic complete
medium (SC) lacking uracil for plasmid selection. Spotting assays were conducted
on YPD (1.5 % agar, 2 % bacto-peptone, 2 % glucose, 1 % yeast extract) and YPEG
(1.5 % agar, 2 % bacto-peptone, 3 % glycerol, 2 % ethanol, 1 % yeast extract) me-
dia. Cells with an OD600 of 0.2 (7 µL) were spotted onto growth media in a series
of 10-fold dilutions. Expression was induced by adding 0.4 % galactose into the me-
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dia. Pictures were taken following incubation at 30°C for 5 days following spotting.
For the yeast Western blots, rabbit anti-FLAG (Rockland) at 1:2000, and mouse
anti-PGK1 (Molecular Probes) at 1:1000 were applied as primary antibodies.
2.3 Mouse and tissue culture experiments
Mouse strains
The cardiac-specific Ctr1 deletion mouse (Ctr1hrt/hrt) was generated by cross-
ing Ctr1flox/flox mice (Dr. Dennis J. Thiele lab at Duke University) with mice ex-
pressing Cre recombinase driven by the promoter of cardiac-expressed alpha-Myosin
Heavy Chain (MHC) (Jackson Lab). Age-matched Ctr1flox/+ or Ctr1flox/flox siblings
not expressing Cre were served as control group (WT) in this study. All mice geno-
type were confirmed by heart Ctr1 excision genotyping PCR, as previously described
in [41], and selected mice heart Ctr1 protein levels were determined by immunoblot.
All mice were maintained on the C57BL/6 genetic background. All animal proce-
dures were performed in accordance with National Institutes of Health Guide and
approved by the Institutional Animal Care and Use Committee at the University of
Maryland, College Park (protocol # R-APR-18-14).
Antibodies
The anti-ATP7A antibody (generous gift from Dr. Betty A Eipper, University
of Connecticut), anti-Ctr1 antibody (generous gift from Dr. Dennis J. Thiele, Duke
University), and anti-β-tubulin antibody (Sigma #T9026), were used at 1:2,000
dilution. The anti-tyrosinase antibody (T311)(Santa Cruz Biotechnology #20035)
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was used at 1:300 dilution. The anti-CCS antibody (Santa Cruz Biotechnology)
and anti-GAPDH antibody (Sigma) were used at 1:1,000 dilution and 1:5,000 dilu-
tion, respectively. The anti-ZO-1 antibody (Invitrogen 33-910-0) and anti-Claudin
5 antibody (Abcam AB15106) were applied at 1:1000 dilution. The anti-MTCO1
antibody (Abcam Ab14705) and the anti-COXIV antibody (Thermo Fisher A21348)
were used at 1:1,000 dilution. The HRP-conjugated anti-mouse or anti-rabbit IgG
(Sigma) were used as secondary antibody at 1:5,000 dilution.
Elesclomol (ES) administration to Ctr1hrt/hrt mice
Starting from postnatal day 5 (P5), 10 mg /kg body weight of ES (Selleckchem)
or vehicle was subcutaneously injected to Ctr1hrt/hrt or WT pups every three days
until P26. During administration, depending on individual mice weight, an appro-
priate amount of ES was dissolved in DMSO, and then mixed with 5 % methyl
cellulose solution (Sigma Cat. #64605) to reach a 2 % final concentration of ES-
DMSO. The vehicle control solution only contains 0.5 % methyl cellulose solution
with 2 % DMSO. Mice body weight was recorded every day from P5 to P26. After
P26, the ES-treated WT and Ctr1hrt/hrt mice were re-grouped, with half of the pop-
ulation continued with 10 mg /kg ES administration once per week (ES-ES), and
the other half switched to vehicle treatment (ES-vehicle). Mice body weight was
recorded every week until P54.
Tissue preparation and immunoblotting
Several tissues were collected from P10-P12 pups after three times of ES ad-
ministration, or from P54 mice following several ES-ES or ES-vehicle treatments.
Tissues were frozen in liquid nitrogen and stored under -80°C before use. In order
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to isolate the intestinal enterocytes, the whole small intestine was cut open, washed
with cold-PBS and incubated in cold PBS containing 1.5 mM EDTA and protease
inhibitor cocktail (Roche) with gentle rotation. After 30 minutes, enterocytes were
release and the rest of intestine containing lamina propria was discarded. The en-
terocytes were then washed twice with cold PBS and collected by centrifugation
at 2000 x g for 3 minutes, stored under -80 °C for subsequent analysis [203]. For
immunoblotting, frozen tissues were homogenized first in cold lysis buffer (PBS pH
7.4, 1 % Triton X-100, 0.1 % SDS, 1 mM EDTA and protease inhibitor cocktail)
with a pellet mixer (VWR) on ice, incubated for 45 minutes with several times of
vortex, and then centrifuged at 15,000 x g, 15 minutes at 4 °C. The supernatant
was transferred to a fresh tube, followed by protein concentration measurement
with a BCA Assay Kit (Thermo Scientific). Equal amounts of protein were loaded
and separated in a 4-20 % gradient gel (Bio-Rad), and then transferred to a nitro-
cellulose membrane. After developing antibodies, immunoblots were detected with
Pico or Femto Chemiluminescent Substrate Reagents (Thermo Fisher) with Bio-Rad
Chemidocumentation Imaging System.
Cardiac tissue histology and immunofluorescence
Freshly collected heart tissues were fixed in 4 % paraformaldehyde/ PBS so-
lution at 4 °C for overnight with gentle agitation, and then washed twice with 100
% ethanol and dehydrated in 70 % ethanol. Paraffin embedding, tissue sectioning
and hematoxylin/ erosin staining were then performed by Histoserv, Inc. Cardiac
myocytes size and morphology were observed with a Leica DMI6000 microscope.
For immunofluorescence, the Alexa Fluro 488 conjugated anti-WGA (Wheat germ
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agglutinin, Invitrogen W11261) was applied to sectioned cardiac tissues at 1:500
dilution. Cells were imaged by a confocal microscope, and 45 cells under each con-
dition were quantified for surface area using Image J.
Mouse embryonic fibroblasts (MEF) culture and tyrosinase and lysyl
oxidase activity assay
Wild-type (ATP7A+/+) and ATP7A-/- MEFs were cultured in Dulbecco’s
Modified Eagle Medium (DMEM; Lonza) supplemented with 10 % (v/v) heat-
inactivated fetal bovine serum (VWR). Cells were cultured at 37 °C with 5 % CO2.
When cells grown to 70 % confluence, single or double plasmids (8 µg DNA /each)
were transfected with the PolyJet transfection reagent (SignaGen). 24 hours af-
ter the transfection, indicated concentrations of ES were administrated into culture
media and incubated for another 24 hours. Cells were then collected for protein
extraction. For tyrosinase activity assay, proteins were extracted with lysis buffer
containing PBS pH 7.4, 1 % Triton X-100, 1 mM EDTA and Halt protease in-
hibitor cocktail (Thermo Fisher). 100 µg protein/sample was fractioned on a 10 %
non-reducing SDS-free polyacrylamide gel. The gel was first stabilized in 50 mM
PBS (pH 6.8) for 30 minutes at room temperature and then stained at 37 °C in
solution containing 10 mM PBS (pH 6.8), 1.5 mM L-3,4-dihydroxyphenylalanine
and 4 mM 3-methyl-2-benzothiazolinone hydrazone (Sigma). The relative activ-
ity of tyrosinase is colormetrically determined by the formation from L-DOPA to
DOPA-chrome [204], and the intensity was quantified by Image J.
Human cerebral microvascular endothelial cells (hCMEC/D3) cul-
ture, permeability assay and transwell co-culture with Ctr1-/- MEFs
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The hCMEC/D3 cells were purchased from CELLutions BIOSYSTEMS and
used between passage 28-32. The final culture media for hCMEC/D3 contains 5 %
(v/v) heat-inactivated fetal bovine serum (VWR), 100 U/mL Penicillin/Streptomycin,
1.4 µM Hydrocortisone (Sigma H0135), 5 µg/ml Acid Ascorbic (Sigma A4544), 1x
Chemically Defined Lipid Concentrate (Thermo), 10 mM HEPES and 1ng/ml bFGF
(Sigma F0291) in EBM-2 media (Lonza). The transendothelial electrical resistance
(TEER) of hCMEC/D3 in transwell inserts was measured with a EVOM2 epithe-
lial voltohmmeter (WPI) daily after plating. hCMEC/D3 used in all transwell
experiments had TEER higher than 60 ohm.cm2. For the permeability assay, ap-
proximately 4x106 hCMEC/D3 cells were plated on the type I rat collagen-coated
transwell insert (for 6-well plates, culture area was 4.67 cm2) for 1, 5 or 10 days;
and then DMSO or 30 nM elesclomol was added to the apical side culture media.
After 24 hours, 4 kDa FITC-dextran (Sigma) was added to the apical side media
at 4.15 mg/ml. 50 µL of basal side culture media was collected every 45 minutes
for fluorescence measurements at 490/530 nm. The permeability coefficient (Pe)
was calculated according to previous studies [205, 206]. For the co-culture assay
with Ctr1 knockout MEF cells (Ctr1-/- MEFs), approximately 4x106 hCMEC/D3
cells were plated on collagen-coated transwell inserts and cultured for 10 days, fol-
lowed by ES administration to the apical side culture media. Simultaneously, Ctr1-/-
MEFs were cultured in the bottom chamber. 24 hours after the ES treatment, both
hCMEC/D3 and Ctr1-/- MEF cells were collected. Wild-type (Ctr1+/+) and Ctr1-/-
MEFs were cultured in DMEM supplemented with 10 % (v/v) heat-inactivated fetal
bovine serum, 1x MEM nonessential amino acids (Lonza), 50 µg/mL uridine, 100
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U/mL penicillin/streptomycin (Lonza), and 55 µM 2-mercaptoethanol.
2.4 Statistical analysis
Immunoblot and tyrosinase activity were quantified using the a Bio-Rad Chemi-
documentation Imaging System or ImageJ. Statistical analysis was performed with
one-way ANOVA followed by Sidak post hoc test, or two-way ANOVA followed by
Tukey’s post hoc test, using GraphPad Prism 6 (GraphPad). ANCOVA was per-
formed using SPSS Statistics version 23 (IBM). Statistical significant differences are
considered at p < 0.05.
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Chapter 3: CHCA-1 is a copper-regulated CTR1 homolog required
for normal development, copper accumulation, and copper-
sensing behavior in Caenorhabditis elegans
3.1 Project summary
Copper (Cu) plays key roles in catalytic and regulatory biochemical reactions
essential for normal growth, development, and health. Dietary Cu deficiencies or
mutations in Cu homeostasis genes can lead to abnormal musculoskeletal develop-
ment, cognitive disorders, and poor growth. In yeast and mammals, Cu is acquired
through the activities of the CTR1 family of high-affinity Cu transporters. However,
the mechanisms of systemic responses to dietary or tissue-specific Cu deficiency re-
main unclear. Here, taking advantage of the animal model Caenorhabditis elegans
for studying whole-body Cu homeostasis, we investigated the role of a C. elegans
CTR1 homolog, CHCA-1, in Cu acquisition and in worm growth, development,
and behavior. Using sequence homology searches, we identified ten potential or-
thologs to mammalian CTR1. Among these genes, we found that chca-1, which
is transcriptionally upregulated in the intestine and hypodermis of C. elegans dur-
ing Cu deficiency, is required for normal growth, reproduction, and maintenance of
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systemic Cu balance under Cu deprivation. The intestinal Cu transporter CUA-1
normally traffics to endosomes to sequester excess Cu, and we found here that loss
of chca-1 caused CUA-1 to mislocalize to the basolateral membrane under Cu over-
load conditions. Moreover, animals lacking chca-1 exhibited significantly reduced
Cu avoidance behavior in response to toxic Cu conditions compared with wild-type
worms. These results establish that CHCA-1-mediated Cu acquisition in C. elegans
is crucial for normal growth, development, and Cu-sensing behavior.
3.2 Results
3.2.1 Cu-responsive transcriptional regulation of CTR1-like genes in
C. elegans
To identify potential genes for Cu acquisition in C. elegans, a Basic Local
Alignment Search Tool (BLAST) search was performed using the human CTR1
protein sequence as a probe. Unlike many characterized organisms that contain two
or three CTR homologs [18, 32, 39, 207], fifteen protein orthologs encoded by ten
gene loci are predicted to be potential C. elegans CTR genes. The BLAST result
scores for the fifteen candidate proteins demonstrate that, in general, worm CTR
candidates share 30-40 % amino acid sequence identity with hCTR1 (Table 3.1).
Worm CTR1 candidate proteins were further analyzed based on the conserved
features of CTR proteins, such as number of the transmembrane domains and Cu-
transporting motifs at the amino (N) and carboxyl (C) terminus, and the second
predicted TMD. In general, C. elegans CTR candidates have a shorter N terminus as
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Table 3.1: C. elegans Ctr homolog genes. PSI-BLAST was conducted to search C.
elegans Ctr candidates using the human CTR1 (hCTR1) amino acid sequence. 10
gene loci that express 17 potential proteins are listed, within which 15 proteins had
E values beneath the threshold of 10-3. F58G6.9c and K12C11.3b (labeled with
#) proteins were among candidate gene loci, but had E values greater than 10-3.
Protein identities, similarities, and scores are listed. Based on known features of
hCtr1, C. elegans Ctr1 candidate proteins were annotated by their conserved Cu
transporter features. Transmembrane domains (TMD) were predicted by TMHMM
1.0, and N-terminal methionine (Met) and histidine (His) enrichment levels were
characterized by calculating the percentage of Met or His before the first predicted
TMD (0–5 % *, 5 %–10 % **, ≥ 10 % ***). All candidate proteins contain Met-X3-
Met domains in or close to one of the predicted TMD (√); non-candidate proteins do
not (-). Proteins labeled with (√) in the last column contain one or more cysteines


























































































































































































































































compared to human and mouse CTR1 (Figure 3.1). Candidate proteins expressed at
F31E8.4, Y58A7A.1, F58G6.3, F58G6.7, and F58G6.9 gene loci are enriched with
both methionine and histidine at the N-terminus. All fifteen candidates contain a
Met-X3-Met domain within or close to one of the predicted TMD.
CTR1 abundance is regulated by Cu availability. In yeast and mammalian
cells, high Cu induces CTR1 protein degradation, while Cu deprivation stabilizes
the protein [36, 208, 209]. In yeast, such regulation occurs at the transcriptional
level. Ctr1 expression is induced under Cu-depleted conditions by the transcriptional
factor Mac1 [4]. To test whether worm CTR mRNA abundance can be regulated by
altered Cu status, qRT-PCR was performed for the ten candidate genes under opti-
mal, high, and low Cu conditions in liquid axenic growth media. To determine the
desired range of Cu concentration for worm growth, the C. elegans Habituation and
Reproduction (mCeHR) axenic liquid culture [119] was further modified to contain
minimal levels of Cu (”low Cu” mCeHR). Around 100 synchronized L1 stage worms
were grown in axenic culture supplemented with various concentrations of copper
chloride (CuCl2) or bathocuproinedisulfonic acid (BCS, a Cu(I) chelator) for 9 days;
total worm number was counted for each condition on day 9. Supplementation with
10 µM Cu was most favorable for worm growth, while worms exhibited the defects in
development or embryogenesis under both Cu-replete and Cu-deficient conditions,
resulting in significantly decreased total populations (Appendix Figure I A). Either
10 µM Cu, 300 µM Cu, or 100 µM BCS was applied to generate normal, strong Cu
overload and strong Cu deficiency conditions, respectively, to measure changes in
gene expression. Synchronized L1 worms were cultured to the L4 stage, and levels
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Figure 3.1: TMD (grey box) and N-terminal Met (short line) alignment for human,
yeast, mouse, and zebrafish Ctr amino acid sequences and worm Ctr candidate
proteins encoded by the 10 candidate gene loci. TMHMM (1.0) was used to identify
TMDs. Proteins are aligned at the position of the first TMD for visualizing the
relative length and Met enrichment at the N-terminus. K12C11.3b has no predicted











































































































of mRNA of each candidate gene under high and low Cu conditions were calculated
by normalizing to expression levels under 10 µM Cu condition. Under Cu deprived
conditions, expression of only F58G6.3, F58G6.7, and F58G6.9 was significantly
elevated (Appendix Figure I B). These three genes, together with other candidate
genes such as F01G12.1, Y58A7A.1, and K12C11.6, had expression suppressed by
300 µM Cu (Appendix Figure I C).
3.2.2 Importance of CTR1 candidate genes for growth, reproduction,
and Cu accumulation in worms
Our recent studies have shown that limited availability of dietary Cu causes
developmental defects in worms, and that depletion of the Cu exporter CUA-1 in the
intestine inhibits Cu distribution to peripheral tissues, resulting in reduced growth
and brood size [126]. To test whether our potential CTR genes were required for
worm growth in a Cu-dependent manner, L1 stage worms were grown on NGM me-
dia plates seeded with OP50 bacteria. Plates were supplemented with either 150 µM
CuCl2, 50 µM BCS, or nothing. Milder Cu conditions were used (as compared to the
experiments with axenic culture) to more closely mimic physiologically-relevant con-
ditions of Cu abundance and deprivation and to enable observation of intermediate
growth phenotypes. Following 3 days of growth, F58G6.9 - and F27C1.2 -depleted
P0 animals cultured with 50 µM BCS were found to be stage-delayed, as indicated
by time of flight (TOF, worm length quantification), in comparison to vector-treated
animals (Figure 3.2 A-D). There were no apparent growth defects observed in worms
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treated with RNAi against other Ctr-like genes under different Cu conditions (Fig-
ure 3.2 A-C) suggesting an important role of the proteins encoded by F27C1.2 and
F58G6.9 in response to Cu deficiency in worms.
To determine the efficiency of knockdown, qRT-PCR was performed to test
candidate gene expression levels after RNAi treatment. All candidate genes’ mRNA
levels were significantly decreased after worms were fed RNAi bacteria. While
F01G12.1, F31E8.4, and K12C11.3 transcripts exhibited a mild reduction (∼80–60
% of wild type expression), silencing of all other CTR candidates was highly effective
(less than 30 % of wild type expression) (Figure 3.3).
To further test whether CTR candidates are important for normal Cu levels in
worms, each gene was individually silenced, and whole-body metal levels were exam-
ined by ICP-MS. When providing synchronized L1 (P0) with sufficient Cu (10 µM)
for two generations, F1 worms lacking a number of the candidate genes displayed
decreased Cu accumulation (73-80 % of that of vector) (Figure 3.4 A). To identify
the gene most strongly associated with Cu accumulation in C. elegans, a Cu-pulse
assay was conducted on each RNAi-treated candidate by pre-culturing worms in
Cu-limited conditions followed by a 12-hour (h) 50 µM CuCl2 pulse (Figure 3.4 B).
Following BCS treatment, all worms had extremely low whole-animal Cu concen-
trations, in a range of 0.03-0.06 µg/g (data not shown). When calculating the level
of Cu acquired during the Cu pulse, F58G6.3 -, F58G6.7 -, and F58G6.9 -depleted
worms displayed significant defects in restoration of Cu levels. Of these, the most
defective were the F58G6.9 RNAi animals, which only accumulated 40 % of the
Cu measured in vector-treated worms (Figure 3.4 C). Depleting a number of other
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Figure 3.2: Requirement of CTR1 candidate genes for Cu-dependent growth. A-C)
Cu-dependent growth assay under basal (A), high Cu (B) and limited Cu (C) con-
ditions. Synchronized L1 stage N2 worms were cultured on RNAi plates until the
vector-treated worms reached L4 stage. Worm length (TOF) was quantified using a
COPAS BioSort system, and worm length under each RNAi condition was normal-
ized to vector TOF. ∼ 400 individual animals were analyzed under every condition.
Values with asterisk are significantly different from vector (one-way ANOVA, Dun-
nett post hoc test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). D) Representative images of

































































































































































































































































































Figure 3.3: RNAi efficiency of 10 CTR candidate genes. N2 worms were
cultured on 50 µM BCS plates from synchronized L1 worms to the L4 stage. Tran-
script levels measured in animals treated with indicated RNAi were normalized to
levels measured in vector-treated animals. Three independent experiments were con-
ducted under each condition. Asterisks indicate significant difference from indicated
gene expression levels under optimal conditions. (t-test, ∗p < 0.05, ∗∗∗p < 0.001,





































































































































candidate genes decreased body Cu accumulation under prolonged Cu treatment
(Figure 3.4 A). However, these conditions did not significantly impact Cu restora-
tion from a Cu-deficient state within the time frame assayed, suggesting that these
genes, when functioning independently, are not required for effective Cu uptake.
Our results narrowed down the CTR-like gene list, leading to F58G6.9 as the
strongest candidate Cu importer in worms. To further explore the role of F58G6.9
in worm regeneration, we measured brood size in F58G6.9 -silenced worms under
Cu-limited conditions. P0 worms after one generation of F58G6.9 RNAi under 50
µM BCS supplementation showed substantially smaller brood sizes compared with
control animals. Similarly, worms treated with F58G6.9 RNAi exhibited severe de-
fects in generating embryos when treated with 100 µM BCS (Figure 3.5). Given
that the F58G6.9 gene showed significantly elevated transcript levels under low Cu
conditions, and that it is required for normal growth, reproduction, and Cu accu-
mulation in a low-Cu environment, we focused on the F58G6.9 gene as a potential
CTR candidate and named it CTR1 Homolog required for Copper Accumulation-1
(chca-1 ).
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Figure 3.4: Requirement of CTR1 candidate genes for Cu accumulation.
A) Cu levels in C. elegans were measured by ICP-MS after exposure to 10 µM Cu
for two generations. Values with asterisk are significantly different from vector with
three independent trials (One-way ANOVA, Dunnett post hoc test, ∗p < 0.05). B)
A schematic presentation of Cu-pulse assays. C. elegans worms were cultured in
axenic media supplemented with 25 µM BCS for 5 days prior to synchronization.
Synchronized L1 animals were cultured on 50 µM BCS NGM agar plates expressing
indicated dsRNA for 72 h. Animals were then washed, aliquoted, and re-plated on
fresh 50 µM BCS or 50 µM CuCl2 plates for 12 h. Restored Cu levels are indicated
by normalizing Cu-treated worms to BCS-cultured animals. C) Restored Cu levels
under indicated RNAi treatments. Values with asterisk are significantly different
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Figure 3.5: F58G6.9 RNAi animals exhibited significantly reduced brood
size. Brood size analysis of F58G6.9 RNAi animals. Error bars indicate mean ±
SEM of five independent experiments. Values with asterisk are significantly different
from vector under same culture condition (Two-way ANOVA, Sidak post hoc test,








































3.2.3 CHCA-1 is required for normal Cu level and development
We tested functional complementation by worm CHCA-1 in yeast cells de-
fective in the high affinity Cu transporters, Ctr1 and Ctr3, on non-fermentable
carbon sources [207]. Expression of CHCA-1 protein with a carboxyl-terminal
FLAG epitope tag (CHCA-1-2xFLAG) in the heterologous system failed to restore
yeast growth (Figure 3.6). To test functional consequence of loss of the endoge-
nous CHCA-1 in vivo system, we exploited an established Cu-responsive CUA-1-
trafficking reporter animal model. Our recent studies have demonstrated that the
intestinal CUA-1.1 Cu exporter maintains systemic Cu homeostasis by altering its
subcellular localization [126]. It localizes to the basolateral membrane during Cu
deficiency, and upon Cu overabundance, re-distributes to lysosome-like organelles,
called gut-granules, to protect peripheral tissues from Cu toxicity. As ICP-MS as-
says only measure whole body Cu levels, we silenced chca-1 in transgenic worms
expressing CUA-1.1::GFP from the constitutive, intestine-specific vha-6 promoter
[210] (BK015 strain) to evaluate whether the depletion of chca-1 yields any change
in intestinal Cu status. Importantly, when given sufficient dietary Cu, worms lack-
ing chca-1 showed CUA-1.1::GFP localized to the intestinal basolateral membrane
with significantly decreased distribution to the gut granules when compared with
vector-treated animals (Figure 3.7 A and Figure 3.8 A). Individual silencing of all
other CTR candidate genes did not change CUA-1.1 localization in the intestine
(Figure 3.7), suggesting the CHCA-1 is a major player in intestinal Cu homeostasis.
Our studies have also shown that endogenous CUA-1.1 expression is induced in the
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hypodermis under dietary Cu restriction [126]. Upon depleting chca-1 in transgenic
worms expressing CUA-1.1::GFP driven by its own promoter (BK017 strain), CUA-
1.1 expression was significantly enhanced in the hypodermis under basal culture
conditions at a comparable level to that of the transgenic strain grown in 25 µM
BCS (Figure 3.8 B). Together, Cu dependent CUA-1.1 distribution and expression
in worms lacking chca-1 was similar to dietary Cu deficient worms, suggesting a role
for CHCA-1 in Cu acquisition in C. elegans.
To further characterize CHCA-1 and to verify the RNAi-based findings, a chca-
1 mutant animal (chca-1 tm6506 IV ) was obtained from the National Bioresource
Project [197]. The tm6506 allele found in this mutant contains a 464-bp deletion
which begins in the 5' UTR and spans the second intron of the F58G6.9 gene;
this deletion is predicted to affect the entire N terminus and first TMD (Figure 3.9
A and B). Worms homozygous for the tm6506 allele exhibited defects in growth
under basal and Cu-replete conditions (10 µM CuCl2) and showed a severe growth
phenotype under BCS treatment within one generation (P0). However, the growth
defects were fully rescued by Cu supplementation at 25 µM (Figure 3.10 A and B).
To test the metal specificity of CHCA-1-dependent growth, 50 µM BCS and
several metal sources (CuCl2, ZnCl2, FeCl2, and MnCl2) were mixed together in
the growth media, and the growth of the tm6506 mutant strain and its wild-type
outcrossing brood mate (WT) were compared after 3 days of culture. Only Cu
supplementation rescued the growth defect observed in chca-1 mutant worms, sug-
gesting a function for this gene in Cu-specific regulation (Figure 3.10 C). Compared
to WT animals, chca-1 tm6506 IV worms contained significantly lower Cu levels
64
Figure 3.6: Expressing F58G6.3, F58G6.7, and F58G6.9b in the MPY17
CTR1∆CTR3∆ yeast strain. Worm Ctr candidate genes and yeast CTR1 (sc-
CTR1) were tagged at the C terminus with 2xFLAG tags. Expression was induced
by adding 0.4 % galactose into growth media. A) Growth assay of CTR1∆CTR3∆
strain expressing scCtr1, F58G6.3, F58G6.7, and F58G6.9b. Media containing a
fermentable carbon source (YPD media with glucose) or non-fermentable source
(YPEG media with ethanol and glycerol) was used in the assay. B) Expression of
the indicated genes assayed by immunoblot using an anti-FLAG antibody. Expres-




































Figure 3.7: CUA-1.1::GFP localization in BK015 worms with Ctr candi-
date RNAi. CTR candidate genes were silenced from the the L1 stage in BK015
worms and cultured on 50 µM BCS or 50 µM Cu plates until the L4 stage. Images































Figure 3.8: Depletion of chca-1 by RNAi decreases intestinal Cu avail-
ability in C. elegans. A) Synchronized L1 stage BK015 transgenic worms
[Pvha-6::CUA-1.1::GFP::unc-54 3'UTR; cua-1 (ok904)] were cultured on NGM agar
plates seeded with E. coli expressing dsRNA against CHCA-1 or vector. CUA-
1.1::GFP localization in L4 worms was examined using confocal microscopy. Scale
bar, 15 µM. B) chca-1 -depleted worms display increased endogenous CUA-1.1::GFP
expression in the hypodermis. BK017 [Pcua-1::CUA-1.1::GFP::unc-54 3'UTR; cua-
1 (ok904)] transgenic animals were maintained on 10 µM CuCl2 plates prior to
synchronization. L1 animals were then re-plated for chca-1 RNAi. After 60 h cul-
ture, CUA-1.1::GFP expression levels in L4 animals were examined using confocal
microscopy. Scale bar, 50 µM.
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Figure 3.9: Schematic of CTR1 and chca-1 gene loci and protein sequence
alignment. A) Schematic of human CTR1 and C. elegans chca-1 gene loci, with
blue-colored ORFs and grey-colored UTR regions. Note that CHCA-1b1 and CHCA-
1b2 isoforms differ at the 5'UTR region but express identical proteins. The deleted
region in the tm6506 allele is indicated by the red bar. Scale bar indicates 100-base
pairs (bp). B) Sequence alignment of hCTR1, CHCA-1a, and CHCA-1b proteins.
Transmembrane domains (TMD) of hCTR1 and deleted regions of CHCA-1a and































Figure 3.10: chca-1 (tm6506) IV worms exhibit growth defect under Cu-
deficient condition. A) and B) Growth of tm6506 animals under various CuCl2 or
BCS-supplemented conditions. Worms homozygous for the tm6506 allele and their
outcrossing wild type brood mates (WT) were cultured from synchronized L1s for
72 h. A) Representative images of animals growing under indicated conditions. B)
Worm growth quantification using a COPAS BioSort system. Error bars indicate
mean ± SEM of around 75 worms. Values with asterisk are significantly different
from WT animals under the same Cu or BCS concentrations (Two-way ANOVA,
Dunnett post hoc test, ∗p < 0.05,∗∗ p < 0.01,∗∗∗∗ p < 0.0001). C) WT and tm6506
mutant worms grown on 50 µM BCS plates or 50 µM BCS plus indicated concentra-
tions of metals. Error bars indicate mean ± SEM of around 100 individual animals.
Means with different letters are significantly different at p= 0.05 (Two-way ANOVA,
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under Cu deficiency (ranging from 15 µM BCS up to 10 µM supplemented Cu condi-
tions), while Fe levels were not affected in mutant worms (Figure 3.11 B); this defect
could only be rescued by supplementing the media with 25 µM CuCl2 (Figure 3.11
A). Consistent with our RNAi-based results (Figure 3.4 C), the mutant worms also
demonstrated defects in dietary Cu acquisition upon Cu-pulse (Figure 3.11 C).
3.2.4 Intestinal CHCA-1 is critical for Cu-dependent growth and Cu
accumulation
To further understand the role of CHCA-1 in Cu homeostasis, transgenic
worms expressing GFP driven by the endogenous chca-1 promoter were used to ex-
amine tissue-specific expression of this gene. While the GFP reporter in this strain
was barely detectable under Cu-replete conditions, it was induced in the intestine
and hypodermis upon severe dietary Cu deprivation (Figure 3.12). Tissue-specific
chca-1 knockdowns were performed to determine the contribution of CHCA-1 in
these two tissues to its systemic role in Cu accumulation. This was performed using
rde-1 mutant animals which are RNAi-resistant. In a whole-animal rde-1 knockout
background, knockdown is only effective in a tissue expressing rde-1 cDNA [211]. In
this study, the intestine- and hypodermis-specific RNAi-sensitive strains (VP303 and
NR222, respectively) were used to deplete chca-1, and their growth was compared
to whole-body chca-1 silencing in the N2 strain. Whole animal RNAi-resistant
(WM27) and muscle-specific RNAi-sensitive (WM118) strains served as negative
controls. After normalizing the growth of chca-1 RNAi worms to vector in both P0
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and F1 generations following RNAi, worms depleted for intestinal CHCA-1 in 100
µM BCS exhibited comparable growth and reproduction defects as to those exposed
to whole-body chca-1 RNAi depletion. On the other hand, worms lacking CHCA-1
only in the hypodermis did not reveal growth defects until the F1 generation un-
der the same Cu-deficient conditions (Figure 3.13A and B). The loss of intestinal
chca-1 was also able to phenocopy the decreased Cu levels observed in a whole an-
imal chca-1 knockdown (Figure 3.14 A and B). These results suggest a dominant
function of intestinal CHCA-1 for Cu-dependent growth under a Cu-limited condi-
tion. Meanwhile, CHCA-1 depletion in both the intestine and hypodermis resulted
in similar effects on Cu accumulation when worms were exposed to 25 µM CuCl2,
a Cu-abundance condition (Figure 3.14 C).
To determine which tissue, when lacking CHCA-1, most significantly con-
tributes to aberrant CUA-1.1 localization in the intestine (Figure 3.8 A), BK014
transgenic worms (Pvha-6::CUA-1.1::GFP) were crossed with each of the WM27,
VP303, and NR222 strains. Compared to a whole-body knockdown effect (Fig-
ure 3.15 d and e), loss of CHCA-1 solely in the intestine or hypodermis was not
sufficient to increase CUA-1.1::GFP basolateral membrane distribution, nor to re-
duce its gut granule expression in the presence of 10 µM Cu (Figure 3.15 n, o, s, t).
These results suggest that both intestinal and hypodermal CHCA-1 play important
roles in regulating Cu level in C. elegans, and raise a possibility that CHCA-1 in
the hypodermis could function to compensate Cu deficiency in the intestine and/or
at the organismal level.
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Figure 3.11: chca-1 (tm6506) IV worms exhibit low Cu levels under Cu de-
ficiency and defect in Cu acquisition. A) Cu levels of tm6506 and WT animals.
Synchronized L1 animals were cultured on indicated concentrations of Cu or BCS-
supplemented media for 60 h and then pelleted for ICP-MS. For each condition, 3 or
4 samples were analyzed. Values with asterisk are significantly different from those
of WT animals (t-test for each treatment, ∗p < 0.05, ∗∗∗p < 0.001,∗∗∗∗ p < 0.0001).
B) Fe levels in tm6506 and WT animals in panel A). Values with asterisk indicate
significant differences between tm6506 and WT animals under indicated conditions
(t-test for each treatment, ∗∗p< 0.01). C) Cu-acquisition capacity of tm6506 worms.
WT or tm6506 worms pre-treated with 15 µM BCS were washed, and separately
cultured on fresh 15 µM BCS or 50 µM CuCl2 NGM plates for 12 h, followed by
ICP-MS analysis. Three independent samples were assayed for each condition. As-
terisks indicate that Cu levels in tm6506 worms post-pulse are significantly different
























































































































































Figure 3.12: Tissue-specific expression of the chca-1 gene. Transgenic ani-
mals expressing GFP driven by the 2.8 kb chca-1 promoter region were cultured on
NGM plates containing 10 µM CuCl2 (a, b) or 200 µM BCS (c-f, same animal, dif-
ferent focus layers). Arrowhead indicates intestine, and arrow indicates hypodermis
















Figure 3.13: Cu-dependent growth following chca-1 gene depletion in spe-
cific tissues. N2, RNAi-resistant strains (rde-1, WM27) and tissue-specific rde-1
expressing strains (VP303, NR222, and WM118) were used to knock down the chca-
1 gene in the indicated tissues (Int: intestine, Hyp: hypodermis, Mus: muscle).
Synchronized L1s were cultured to the L4 stage (panel A, P0), or re-synchronized
and cultured for another generation (panel B, F1) on indicated Cu-deficient NGM
plates prior to quantification. Under each condition, ∼200 P0 or F1 worms’ TOF
was quantified by a COPAS BioSort. Growth of chca-1 -depleted worms was nor-
malized to vector for each condition. chca-1 RNAi in N2 and VP303 strains on
100 µM BCS plates exhibited severe defects in P0 reproduction (U.D., under detec-
tion limit). Error bars indicate mean ± SEM of ∼200 individual animals. Values
with asterisks are significantly different from the same strain under basal conditions





































































































Figure 3.14: Intestinal CHCA-1 plays a dominant role in Cu acquisition
under Cu-limited conditions. A and B) Cu accumulation in N2 and tissue-
specific chca-1 -depleted animals. Different strains of worms were pre-cultured on 50
µM BCS NGM plates and then half of the population was separated and treated with
Cu. A) Restored Cu levels after normalizing to BCS-cultured samples. Error bars
represent mean ± SEM of four independent experiments. Values with asterisk are
significantly different from vector (Two-way ANOVA, Sidak post hoc test, ∗∗∗p <
0.001,∗∗∗∗ p < 0.0001). Cu levels following BCS pre-culture were not significantly
different among strains by Two-way ANOVA (data not shown). B) Percentage of Cu
levels restored by chca-1 RNAi after normalizing to vector animals under the same
conditions. Error bars, mean ± SEM of four independent experiments. Values with
asterisk are significantly different from one another (One-way ANOVA, Dunnett post
hoc test, ∗p < 0.05,∗∗ p < 0.01, ns = not significant). C) Synchronized L1 stage N2,
tissue-specific RNAi strains and RNAi-resistant worms treated with with indicated
RNAi were cultured on 25 µM CuCl2 NGM plates for 60 h, followed by washing and
pelleting for ICP-MS analysis. Data from four individual experiments were analyzed
















































































































































































Figure 3.15: Effect of tissue-specific chca-1 RNAi on intestinal CUA-1.1::GFP distri-
bution. BK014 transgenic animals expressing intestinal CUA-1.1::GFP were crossed
with RNAi resistant or tissue-specific RNAi sensitive strains (WM27, VP303 and
NR222). CUA-1.1::GFP distribution was observed at L4 stage by confocal mi-













































3.2.5 CHCA-1 localizes to intracellular vesicles in the intestine
Given the importance of enterocytes in regulating dietary Cu uptake, we gen-
erated transgenic worms expressing a CHCA-1::GFP fusion protein driven by the
intestine-specific vha-6 promoter. This fusion protein localizes to vesicles through-
out the intestine under basal, Cu-deficient, and Cu-replete conditions (Figure 3.16 A
and B). In addition, CHCA-1::GFP expression levels were not altered by Cu avail-
ability (Figure 3.16 C). While CUA-1.1 co-localized with a fluorescent Cu probe
(CF4) in gut granules [126] CHCA-1::GFP did not co-localize with CF4 or gut gran-
ules, the latter of which are auto-fluorescent (Figure 3.16 B and Figure 3.17). To test
whether GFP-tagging could lead to CHCA-1 protein mislocalization, a 2xFLAG tag,
followed by a stop codon and an SL2 splicing leader sequence, were inserted between
CHCA-1 and GFP (Pvha-6::CHCA-1-2xflag::SL2::GFP). Both GFP and FLAG tags
in this study were placed at the C-terminus of CHCA-1 to avoid N-terminal trunca-
tion observed in mammalian Ctr1 [21]. Immunofluorescence analysis showed similar
vesicle localization of FLAG-tagged CHCA-1 protein (Figure 3.18). The function
of intestinal CHCA-1 was then tested by crossing the transgenic worms express-
ing WT CHCA-1 (Pvha-6::CHCA-1::SL2::GFP) driven by an intestine-specific pro-
moter onto a tm6506 mutant background. Transgenic worms expressing WT CHCA-
1 in the intestine in the tm6506 mutant background exhibited significantly rescued
tm6506 growth during Cu deficiency (Figure 3.19). These results suggest a role
for vesicular CHCA-1 in mediating Cu acquisition in the worm intestine, and that
CHCA-1 protein abundance, in contrast with mammalian CTR1, is not regulated
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by Cu status.
3.2.6 CHCA-1 is required for behavioral avoidance of potentially
toxic levels of Cu
Animals navigate complex natural environments containing both dangerous
and valuable items, such as predators and food. C. elegans must approach and
obtain nutrients while avoiding various threats, which include toxic levels of Cu.
Worms detect threats via primary sensory neurons that then propagate such infor-
mation through an interneuron network to ultimately reach pre-motor command
interneurons that direct controlled locomotion. Thus far, several ciliated sensory
neurons (ASH, ASE, ADL, ASI, and ADF) are known to correlate with Cu sensing
and/or avoidance behavior [212, 213]. We studied whether altered Cu status in a
worm affects its Cu avoidance behaviour. To quantify levels of avoidance, assays
were performed on rectangular plates containing a gradient of CuCl2, from no Cu
supplementation on one end, to toxic Cu levels on the other end. After production,
assay plates were kept in a cold chamber for a defined period of time to allow for Cu
diffusion and concentration gradient formation, and marked in sections (Figure 3.20
A). With Cu supplementation, plates generated with the method described above
contain a sharp Cu gradient ranging from section 3 to section 5, as measured by
ICP-MS performed on agar samples from the gradient plates (Figure 3.20 B).
Stage-synchronized L4 young adult worms were seeded in the middle of the
bacteria-free Cu gradient plates, and worm distribution after 2.5 h was visualized.
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Figure 3.16: Expression of CHCA-1::GFP in the intestine. A) Intestinal expression
of CHCA-1::GFP under basal conditions (Pvha-6 ::CHCA-1::GFP, unc-54 3'UTR).
Scale bar, 50 µM. B) CHCA-1::GFP expression in the intestine under basal, Cu-
deficient, and high Cu conditions. A DAPI channel was used to observe intestinal
auto-fluorescence from gut granules. Scale bar, 15 µM. C) CHCA-1::GFP signal
intensity was quantified under high, low, or replete Cu conditions using a COPAS
BioSort system. At least 100 synchronized L4 CHCA-1::GFP-expressing worms were
used following 2.5 days of growth in Cu or BCS-supplemented cultures per condition




















































A                                                                                           
B C
89
Figure 3.17: CHCA-1::GFP does not co-localize with the Cu probe CF4.
CF4 Cu probe staining. Transgenic worms expressing CHCA-1::GFP in the intes-
tine were cultured for 60 h from the L1 stage on 25 µM CuCl2 or 50 µM BCS-
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Figure 3.18: Expression of CHCA-1-2xFLAG protein in the intestine. Syn-
chronized L1 worms expressing CHCA-1-2x FLAG::SL2::GFP in the intestine were
incubated on basal, 50 µM BCS, or 75 µM CuCl2 media for 55 h before being
washed from plates and fixed on slides. Animals stained with secondary antibody
only (Alexa594) served as negative controls. Images were taken with confocal mi-























Figure 3.19: Intestinal expression of CHCA-1 partially rescued growth
of chca-1 mutant animals. Transgenic animals expressing CHCA-1::SL2::GFP
protein were crossed with tm6506 animals to generate an intestinal CHCA-1 ex-
pression animal in a whole body chca-1 mutant background. These transgenic
animals, together with their wild-type brood mates (WT), as well as tm6506 ani-
mals, were quantified by TOF after 60 h culture from synchronized L1s in indicated
conditions. Error bars indicate mean TOF ± SEM of ∼150 individuals. Values
with asterisk are significantly different from tm6506 worms cultured under indi-
cated conditions (Two-way ANOVA, Tukey’s post hoc test, ∗p < 0.05,∗∗ p < 0.01,




















































Figure 3.20: Design of Cu avoidance assay. A) Schematic of Cu avoidance assay:
Cu gradient plates were made by adding a given concentration of CuCl2 to one side
of a rectangular plate. Non-Cu containing plates were used as controls. At least 150
animals were used on each plate with total three independent experiments. B) Cu
levels of 10 mM Cu-gradient plates. 15 agar samples (a-o) were evenly taken from
the five sections (1-5) in Cu gradient or non-Cu supplemented plates (3 samples per
subsection) for ICP-MS analysis. Inset shows detailed measurements for samples
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During quantification, each plate was evenly divided into five sections (with section
5 representing the highest Cu level area), and a formula was used to calculate the
avoidance index (AI) as described in the Methods.
We observed that wild type N2 worms on the Cu gradient plates (10 mM
Cu) had a strong tendency to avoid high Cu-containing areas (Figure 3.21 A) as
compared to normal distribution of worms on non-Cu plates. Changing the max-
imum concentrations found in the Cu gradient from 1 mM to 10 mM led to N2
worms exhibiting enhanced avoidance (Figure 3.21 B) For further assays, 8 mM or
10 mM Cu gradients were chosen in order to achieve clear resolution under tested
conditions. On 8 mM Cu gradient plates, che-2 mutant animals (CB1033), of which
sensory cilia formation are defective [214], lacked Cu avoidance behavior compared
with N2 worms, supporting the importance of the chemosensory axis in Cu sens-
ing. Meanwhile, chca-1 (RNAi) worms demonstrated decreased levels of avoidance
(Figure 3.21 C), suggesting that CHCA-1 is required for a role in sensing and avoid-
ing toxic Cu concentrations. To test whether altered systemic Cu levels in chca-
1 (RNAi) worms result in changes to avoidance behaviors, both Cu-deprived and
Cu-overloaded worms were generated by pre-culturing N2 worms in 100 µM BCS or
100 µM Cu conditions, and along with N2 worms cultured in basal media, placed
on Cu gradient and non-Cu plates. The Cu-deficient worms exhibited less avoid-
ance compared with non-pre-cultured worms, which recapitulated the behavior of
chca-1 (RNAi) worms. However, interestingly, Cu-overloaded worms also revealed
less avoidance of toxic Cu (Figure 3.21 D). These results suggest that C. elegans
Cu sensing behavior is correlated with abnormal Cu levels, although the precise
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mechanisms that determine this behavior remain elusive.
Cu is known to be crucial for the neuropeptide maturation process through
the Cu-dependent peptidyl-glycine alpha-amidating monooxygenase (PAM) [90]. To
test whether neuropeptides are important for Cu-sensing behavior in worms, using
RNAi hypersensitive strains that allow mRNA silencing in neurons [215], the pro-
protein convertase egl-3 and the carboxy peptidase egl-21 were silenced individually
[216, 217] and a significantly decreased avoidance behavior was observed (Appendix
Figure II A). Furthermore, depletion of all predicted PAM orthologs in C. elegans
(pgal-1, pghm-1 and pamn-1 ) caused reduced Cu avoidance (Appendix Figure II B).
Gene silencing efficiency was tested by qRT-PCR performed in parallel to the RNAi
experiments. After RNAi treatment, mRNA levels of che-2, egl-3, egl-21 and PAMs
were decreased (Figure 3.22). Taken together, our results suggest that Cu-sensing
and/or corresponding behavior of C. elegans is associated with the Cu-dependent
neuropeptides maturation in neurons that requires CHCA-1 activity and balanced
body Cu levels.
3.3 Discussion
Cu acquisition via Cu transporter (CTR) family proteins is critical for survival
during fluctuations in environmental Cu levels. Our studies reveal that, similar to
yeast, fish, and mammals, worms lacking CHCA-1 have lower systemic Cu levels and
exhibit profound growth and reproductive defects under low Cu availability. Our
results with worm CTR candidates also suggest that the pathway for Cu traffick-
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Figure 3.21: CHCA-1 is required for Cu sensing and Cu-dependent avoid-
ance behavior. A) Representative results of N2 worm distribution on a non-Cu
plate (left) or 10 mM Cu-gradient plate (right). Error bars, mean ± SEM of two
independent experiments. Asterisk indicate the percentage of animals in the low Cu
area (sections 1 and 2) is significantly different from the percentage in the high Cu
area (sections 4 and 5) (Two-way ANOVA, Sidak post hoc test, ∗∗p < 0.01, ns = not
significant). B) N2 worm avoidance index on Cu gradient plates with varied concen-
trations of Cu. Error bars indicate mean ± SEM of three independent experiments.
Asterisk values are significantly different from the avoidance index on non-Cu plates
(One-way ANOVA, Dunnett post hoc test, ∗∗∗p < 0.001,∗∗∗∗ p < 0.0001). C) Avoid-
ance index of CB1033 (che-2 (e1033) X) and N2 vector worms or chca-1 RNAi
worms on 8 mM Cu gradient plates. Three independent experiments for CB1033
and six independent experiments for N2 were analyzed (One-way ANOVA, Dunnett
post hoc test, ∗p < 0.05,∗∗∗ p < 0.001). D) Worms were pre-cultured with 100 µM
CuCl2 or 100 µM BCS for one generation and assayed on 8 mM Cu gradient plates.
(One-way ANOVA, Dunnett post hoc test, ∗∗∗p < 0.001,∗∗∗∗ p < 0.0001).
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Figure 3.22: The efficacy of RNAi treatments is assessed by qRT-PCR.
TU3335 worms treated with vector or indicated RNAi were cultured under basal
condition till L4 stage followed by qRT-PCR analysis. Results from three or four in-




























































































ing to the secretory pathway via the CTR1-ATOX1-ATP7A/B axis in mammals is
conserved in worms. C. elegans can thus be exploited as a facile whole live animal
system to isolate novel components regulating Cu homeostasis, as well as providing
additional insight into known components.
For example, the fact that C. elegans CHCA-1 is predicted to lack a third
TMD, as well as lacking a C-terminal cysteine or histidine residue, calls into question
the minimal structural requirements for a high affinity Cu transporter. Additionally,
while yeast Cu metabolism components are regulated transcriptionally, and mam-
malian Cu metabolism components are generally regulated at the post-translational
level, worms exhibit characteristics of both. CTR homolog genes, such as F58G6.3
and F58G6.7, are transcriptionally regulated by Cu. The worm ATP7A/B homolog,
CUA-1, is regulated both transcriptionally and post-translationally [126]. C. ele-
gans may thus shed light on the evolutionary history of Cu metabolism regulation.
Importantly, we show differing contributions of CHCA-1 to systemic Cu metabolism
depending on whether it is expressed in the intestine or in the hypodermis. Thus,
C. elegans also provides insight into coordination of Cu homeostasis in multi-tissue
organisms.
Uncovering ten CTR candidate genes in C. elegans was unexpected, as other
model organisms contain fewer CTR homologs. Individually silencing these candi-
date genes did not severely affect worm growth or Cu accumulation under basal or
Cu replete conditions (Figure 3.2 A and Figure 3.4 A). While non-CTR ortholog
metal importers could contribute to dietary Cu uptake in C. elegans, it is also likely
that several CTR genes function redundantly, or that CTR proteins form higher-
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order heteromultimers which serve as fully active Cu transporters [218]. Considering
that CHCA-1 is dominantly enriched only in the intestine and hypodermis, it is pos-
sible that other CTR proteins in C. elegans are expressed in different tissues, and/or
are required under different Cu conditions or during specific developmental stages.
While studies demonstrate that mammalian CTR1 constitutively cycles from
endosomal compartments to the plasma membrane in many cultured cell lines [208],
and endogenous mouse CTR1 is localized to both the apical membrane and intra-
cellular compartments of intestinal epithelial cells in mouse models [41], our data
demonstrate that CHCA-1 localizes mainly to intracellular vesicles with minimal lo-
calization to the apical membrane. Reports in C. elegans have identified lysosome-
like compartments known as gut granules in the intestine that could serve as a
buffering subcellular organelle by transporting metals in the compartment under
Cu or Zn overload conditions [126, 219]. It is plausible that Cu stored in gut gran-
ules could be recycled by CHCA-1 upon Cu-starvation. However, CHCA-1::GFP
was not found to co-localize with gut granules. These results suggest that CHCA-1
may function to transport Cu across from the lumen of an as-yet-unidentified in-
tracellular compartment, while other Cu importers drive Cu transport across the
plasma membrane. Further studies will be necessary to ascertain whether CHCA-1
is important for the mobilization of Cu from endosomes.
In addition to the intestine, a significant induction of chca-1 expression in the
hypodermis is also observed under Cu deprivation. Similarly, cua-1 abundance also
increases in the hypodermis during Cu deficiency, for which regulation may also
occur at the transcriptional level [126]. The hypodermis is known to play a role in
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Fe [220] and heme homeostasis in worms [221]; as such, these findings strengthen its
potential role in Cu homeostasis. It is plausible that hypodermal CHCA-1 acquires
Cu to incorporate into the secretary pathway through CUA-1 activity. Alternatively,
CHCA-1 in the endosomes together with CUA-1 in the plasma membrane may
function to recycle stored Cu in the hypodermis to peripheral tissues in response to
systemic Cu deficiency, as the worm hypodermis is known to store other nutrients
[222].
Dwelling in the soil, C. elegans encounters a complicated and mercurial en-
vironment requiring flexible responses to pathogen exposure, gas composition, and
temperature transitions, as well as undesirable nutrient concentrations. Behavioral
studies in worms under varying environmental stimuli have led to important discov-
eries, establishing the sensing and signaling axis towards CO2/O2 and temperature
[223, 224, 225, 226, 227]. High concentrations of Cu are used as a chemical repellent
and several Cu chemosensory neurons have been identified [212, 213]. In this study,
CHCA-1 was shown to be required for sensing and avoiding Cu, possibly via down-
stream effects of systemic Cu scarcity, as worms lacking CHCA-1 or with limited
dietary Cu sources both revealed significantly decreased avoidance to toxic levels
of Cu. Further experiments suggest that a neuropeptide maturation process, which
is Cu-dependent in many organisms, is involved in worm Cu sensing and avoiding
(Appendix Figure II). Cu deficient worms may have an increased capacity to uptake
Cu and to be resistant to toxic Cu levels, resulting in decreased avoidance in the
time frame of our assays. Alternatively, this altered behavior may be due to defects
in biogenesis of neuropeptides required for Cu sensing, or altered signal transmission
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to downstream interneurons or motor neurons.
An unanticipated observation from our studies was that dietary Cu-overload
worms also showed reduced avoidance of toxic Cu. It is reported that acute Cu
exposure induces ASH neuron activity, but repeated Cu stimulation leads to the
reduction in the avoidance response and in ASH neuronal activity. This may result in
changes to receptor activity and any downstream signaling pathways [228]. Another
explanation could be the failure of sensing caused by Cu toxicity during pre-culture
in high Cu conditions [229]. Is there a Cu-specific receptor on the neuronal cell
surface that elicits subsequence behavioral responses? Could there be a Cu-sensing
olfactory receptor? While the vertebrate olfactory system has a single receptor gene
expressed in each sensory neuron [230], worms have limited numbers of chemosensory
neurons, with multiple receptors expressed in one sensory neuron. There are ∼1300
receptor genes found based on phylogenetic analysis. While electrical and hormonal
signals are commonly used for neuronal signaling, neuropeptides, many of which
are thought to be Cu-dependent, function as crucial signaling regulators as well
[231, 232]. Identification of the essential components in the signaling events will
provide leads for future studies seeking to understand Cu-responsive decision-making
and behavior in C. elegans.
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Chapter 4: The copper-binding pharmacological agent elesclomol re-
stores systemic copper deficiency in Caenorhabditis ele-
gans and Mus musculus
4.1 Summary of the project
Copper (Cu) is a crucial micronutrient that serves as a cofactor for several
enzymes such as cytochrome c oxidase for energy production. Failure to supply suf-
ficient Cu to Cu-dependent enzymes is correlated with developmental and neurolog-
ical disorders. In humans, Cu deficiency is associated with Menkes disease (MNK),
a severe disease caused by mutations in the Cu transporter ATP7A. A recent study
revealed the potential of the anti-cancer drug elesclomol (ES) to restore intracellular
Cu homeostasis and mitochondrial function in cells lacking the expression of several
Cu transporters and chaperones. In our study, we further investigated this drug
using several genetic models of Cu-deficiency. In chca-1 -depleted C. elegans (or-
tholog of the Cu importer Ctr1 ), ES administration fully rescued the growth defect
and Cu levels under Cu-deprived culture conditions. In addition, ES also restored
the lethality in worms lacking cua-1 (ATP7A ortholog) expression, suggesting ES-
mediated restoration of dietary Cu uptake into intestine and to peripheral tissues
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in C. elegans. In cardiac-specific Ctr1 knockout mice (Ctr1hrt/hrt), subcutaneous
injection of ES significantly rescued lethality, developmental retardation, and car-
diac mitochondrial function. Aberrant elevation of ATP7A protein in the liver and
intestine in Ctr1hrt/hrt in response to cardiac Cu deficiency also returned to normal
levels after ES treatment. In cultured cells, ES mediated Cu transport through tight
junctions of blood-brain-barrier (BBB) cells. Meanwhile, ES was found ineffective
in delivering Cu to the cuproenzyme tyrosinase in the absence of ATP7A in vitro.
Our study reveals the capability of ES to rescue Cu deficiency in mouse and C.
elegans independent of Cu transporters, and sheds light on the clinical application
of ES in Cu-deficiency diseases.
4.2 Results
4.2.1 Elesclomol chemically rescues chca-1 phenotypes in C. elegans
ES was first characterized using Ctr1-associated Cu-deficiency models. Cu
import through Ctr1 is crucial for organisms to maintain Cu homeostasis, and im-
paired Cu uptake results in defects in growth, development, and causes neurological
disorders. In C. elegans, loss of function of CHCA-1, a Ctr1 ortholog expressed
in the intestine and hypodermis resulted in reduced Cu accumulation in the whole
worm, as well as growth retardation and embryogenesis defects under low Cu con-
ditions [233]. Mutant chca-1 worms (chca-1 (tm6506) IV ) and wild-type brood
mates (WT) were synchronized by bleaching and L1 larva were plated on NGM
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growth media containing 0 or 100 µM bathocuproinedisulfonic acid (BCS), a Cu(I)
chelator. Additionally, 10 µM copper chloride (CuCl2) or various concentrations of
ES (from 0.1 to 50 µM) were added to BCS-containing plates. After three days,
tm6506 worms exhibited a slight developmental delay under basal conditions and
a severe growth defect when grown on low Cu. This defect could be fully rescued
by adding Cu to the media (Figure 4.1 A). ES supplementation was able to rescue
growth of tm6506 worms in a dose-dependent manner. Quantification of worm
body length suggested that rescue of tm6506 worm growth occurred with 5 µM
or higher concentrations of ES added to 100 µM BCS-containing media, until full
growth rescue was achieved with 50 µM ES supplementation (Figure 4.1 B). Addi-
tionally, the reduced overall Cu levels found in tm6506 animals were fully restored
by ES supplementation (Figure 4.1 C).
4.2.2 ES administration rescues lethality, growth defects and cardiac
hypertrophy found in cardiac-specific Ctr1 knockout mice
Cardiac-specific Ctr1 depleted mice (Ctr1hrt/hrt) were chosen in order to further
characterize ES using a Cu-deficient mammalian model. Ctr1hrt/hrt mice exhibit
cardiac hypertrophy, low bioavailable Cu in the heart, and increased Cu levels in
the serum. Compared to wild-type mice, Ctr1hrt/hrt mice showed reduced weight
gain around P6 or P7, and the median survival of mutant mice is P10 [102]. In
this study, 10 mg/kg of ES or vehicle were given to Ctr1hrt/hrt mice (KO) and
their wild-type littermates (WT) via subcutaneous injection once every three days
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Figure 4.1: Elesclomol rescues growth retardation and Cu levels in chca-1 depleted
C. elegans. A) Representative images of chca-1 depleted worms (tm6506 ) treated
with ES under Cu-deficient conditions. Wild-type (WT) brood mates and tm6506
worms were synchronized and L1 stage worms were then seeded on basal NGM
media or media containing 100 µM BCS. 10 µM Cu or various concentrations of ES
(from 0.1 to 50 µM) were simultaneously added to the media. An equal volume of
DMSO was added to every culture plate as a vehicle control. Images were taken
72 hours after seeding worms. B) Worm body length quantification (TOF, time of
flight) by the COPAS BioSort system. Groups with different letters are significantly
different from each other at p = 0.05 (one-way ANOVA, Sidak post hoc test). C)
Total worm body Cu levels measured by ICP-MS with three biological replicates.
Significance among treatments are labeled with asterisk (****p < 0.0001, **p <
0.01, *p < 0.05, one-way ANOVA, Bonferonni’s post hoc test). Error bars represent
mean ± SD.
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starting from P5. As reported previously, administering 25-100 mg/kg ES to a
tumor-bearing nude mouse model did not show any toxic effects on either cancerous
or normal cells [149]. Therefore, the dose of 10 mg/kg of ES used in this experiment
is likely to be a safe dose for wild-type mice.
While all vehicle-treated Ctr1hrt/hrt pups began to lose weight from P7 and
died by P12, ES-treated KO pups showed normal development and weight gain
compared to WT (Figure 4.2 A). To test whether ES supplementation up to four
weeks of age is sufficient to rescue the developmental defect of Ctr1hrt/hrt mice, ES-
injected WT and KO mice were regrouped on P26, where half of the mice continued
to receive ES while the other half were switched to vehicle. Note that the injection
interval was extended from three days to one week. After being switched from
ES to vehicle, Ctr1hrt/hrt mice continued to gain weight and showed no significant
difference in body mass compared to other groups (Figure 4.2 B). The genotypes of
all mice used in this study were confirmed by PCR using heart genomic DNA, as
described previously [110] (Figure 4.3 A). Cardiac Ctr1 protein levels were tested
by immunoblot using tissue lysates from P12 mice, and Ctr1hrt/hrt mice showed
decreased expression of both glycosylated and truncated forms of Ctr1 (17 kDa and
35 kDa, respectively) (Figure 4.3 B). These results indicate that Ctr1 was partially
deleted in Ctr1hrt/hrt mice, and the deletion was sufficient to cause growth and
survival defects. Importantly, ES injection did not alter Ctr1 depletion efficiency or
protein expression levels.
P10 Ctr1hrt/hrt mice were examined to determine the effect of ES on growth
defects and cardiac hypertrophy. Ctr1hrt/hrt mice on P10 (after only two ES injec-
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tions) appeared normal in size, and the body mass was fully rescued compared to
WT (Figure 4.4 A and B). While vehicle-treated Ctr1hrt/hrt mice exhibited enlarged
hearts (with a higher heart/body mass ratio), ES administration significantly res-
cued heart size back to WT levels (Figure 4.4 C). Furthermore, Ctr1hrt/hrt mice
exhibited absent or tiny thymus sizes and smaller spleens compared to wild-type.
Cu has been suggested to play a crucial role during lymphatic organ development,
as dietary Cu-deficient mice had underdeveloped thymus glands with reduced Cu
accumulation and low cytochrome c oxidase activity [234, 235, 236]. However, the
mechanism for this is not understood. In Ctr1hrt/hrt mice, ES administration sig-
nificantly restored the thymus and spleen sizes to normal mass ratios (Figure 4.4
D and E). Meanwhile, WT mice after ES treatment revealed no difference in body
mass/tissue mass ratio compared to vehicle-injected WT (Figure 4.4 B-E).
4.2.3 Cardiac Cu deficiency in Ctr1hrt/hrt mice can be restored by
ES-dependent Cu delivery
Ctr1hrt/hrt mice exhibit enlarged cardiomyocytes, reduced Cu levels and de-
creased Cco component abundance in their heart compared to WT mice. Cardiomy-
ocyte morphology was observed by hematoxylin and eosin staining. P10 Ctr1hrt/hrt
mice exhibited enlarged cardiomyocytes with large nuclei. Upon ES treatment, cell
sizes were decreased in these knockout mice (Figure 4.5 A). Immunostaining of WGA
(wheat germ agglutinin) in these tissues revealed a significantly reduced cell surface
area, though not reduced to the size of cadiomyocytes in WT mice (Figure 4.5 B and
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C). Next, cardiac Cu levels were determined using inductively coupled plasma mass
spectrometry (ICP-MS). After two ES injections, P10 Ctr1hrt/hrt mice exhibited in-
creased cardiac Cu levels, through again, not rescued to the levels in WT mice.
ES-injected WT mice accumulated more Cu in their hearts than vehicle-injected
WT mice (Figure 4.6 A). Bioavailable Cu levels were estimated using CCS (Cu
chaperone for Cu, Zn superoxide dismutase) protein abundance, the expression of
which is stabilized by Cu-deficiency in Ctr1hrt/hrt mice. After ES injections, the car-
diac CCS abundance of Ctr1hrt/hrt mice was similar to WT levels (Figure 4.6 B and
C), suggesting that ES could mediate Cu delivery into cardiac tissues. Furthermore,
the abundance of cytochrome c oxidase component Cox1 in hearts of P10 Ctr1hrt/hrt
mice was significantly increased by ES administration, though not restored to WT
levels after two injections (Appendix Figure III). After extending the ES treatment
until P26 or P54, the Cco components abundance in Ctr1hrt/hrt mice were similar
to levels found in WT mice (Figure 4.6 D,E and F). Taken together, these findings
suggest that Cu delivery through ES to Ctr1 -depleted cardiac cells could restore the
abnormal cardiomyocyte morphology and mitochondrial function.
4.2.4 ES supplementation rescues the altered systemic ATP7A pro-
tein levels of Ctr1hrt/hrt mice
Ctr1hrt/hrt mice show elevated serum Cu levels, as well as elevated ATP7A
Cu exporter protein abundance in the liver and the intestine epithelial cells. It
is hypothesized that ATP7A may be able to mobilize Cu from Cu absorption and
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Figure 4.2: ES injection rescues lethality and growth retardation of cardiac-specific
Ctr1 knockout mice. A) Control littermates (Ctr1flox/flox or Ctr1flox/+, referred
to as WT), or cardiac-specific Ctr1 depleted mice (Ctr1hrt/hrt, referred to as KO)
were injected subcutaneously with 10 mg/kg body weight of ES or vehicle (0.5 %
methyl cellulose solution containing 2 % DMSO). Injections were performed once
every three days from postnatal day 5 (P5) until P26, and body weight was recorded
every day. The number of mice treated under each condition are indicated (N). The
three vehicle treated KO mice were found dead on P8, P12 and P12. No death
was found in ES-injected KO mice. Asterisk marks indicate significant difference
compared to the WT vehicle group (two-way ANOVA, Tukey’s post hoc test, ∗p
< 0.05, ∗∗∗p < 0.001). B) ES supplemented WT or KO mice were split on P26,
half of the mice continued with ES injection once per week, and the other half were
switched to vehicle treatment. Body weight was recorded once a week until P54. No
significant difference was found among groups by two-way ANOVA. For the entire
figure, error bars represent mean ± SD.
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Figure 4.3: Cardiac Ctr1 excision efficiency in Ctr1hrt/hrt mice. A) Representative
genotyping result from Ctr1flox/flox and Ctr1hrt/hrt heart genomic DNA at P10. The
lower 241 bp band and the upper 281 bp band reflect the floxed Ctr1 allele and the
deleted Ctr1, respectively. B) Cardiac Ctr1 and CCS protein abundance from WT
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Figure 4.4: Abnormal body mass and organ sizes in Ctr1hrt/hrt mice are rescued by
ES supplementation. A) Cardiac Ctr1 KO mice and WT littermates at P10 after
ES or vehicle treatment. Scale bar, 1 cm. B) Quantification of mouse body weight
under each treatment condition. Mouse numbers are indicated (N). C-E) Relative
organ sizes, presented as organ weight /body weight, for heart (C), spleen (D), and
thymus (E). Representative organ images are provided below each panel. Scale bars,
1 cm. For panel B-E, differences among groups are analyzed by one-way ANOVA
(Sidak post hoc test), groups with different letters are significantly different from
each other at p= 0.05. For the entire figure, error bars represent mean ± SD.
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Figure 4.5: ES administration rescues cardiac hypertrophy of Ctr1hrt/hrt
mice. A) H&E staining of heart sections from P10 Ctr1hrt/hrt and WT littermates
supplemented with vehicle or 10 mg/kg ES on P5 and P8. Scale bars, 25 µm. B) and
C) Quantification of cardiomyocyte surface area. P10 heart sections were immuno-
stained with wheat germ agglutinin, and cell surface area was quantified by Image J
(45 cells for each condition). Groups with different letters are significantly different
from each other at p = 0.05 (one-way ANOVA, Sidak post hoc test). Error bars,
mean ± SD. Scale bars, 25 µm.
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Figure 4.6: ES restores bioavailable Cu levels and Cco abundance in
Ctr1hrt/hrt mice cardiac tissue. A) Cu levels in cardiac tissues from P10 WT
or in Ctr1hrt/hrt mice supplemented with vehicle or 10 mg/kg ES on P5 and P8.
N=3 or 4 for each condition. Error bars, mean ± SD. Differences among groups
are analyzed by one-way ANOVA at p = 0.05 (Sidak post hoc test) and indicated
by differing letters. B) Representative Western blot results and C) quantification of
cardiac CCS abundance in P10 mice with vehicle or ES treatment. N=4 for each
treatment. Tubulin abundance serves as loading control. Groups with different let-
ters are significantly different from each other at p= 0.05 (one-way ANOVA, Sidak
post hoc test). Error bars, mean ± SD. D) Representative Western blot of P54
mice cardiac tissue ETC complex IV and its subunit protein abundance. E) and
F) Quantification of COX1 and COXIV abundance from D). N=3 for each condi-
tion. Tubulin abundance serves as loading control. Groups with different letters
are significantly different from each other at p = 0.05; ns, not significant (one-way
ANOVA, Sidak post hoc test). Error bars, mean ± SD.
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storage sites to the Cu-deficient cardiac tissue, and that the heart may communi-
cate with both of these tissues by secreting signaling molecules into the serum in
order to induce hepatic and intestinal ATP7A expression [102]. In this study, ES
treatment suppressed ATP7A protein abundance in P10 or P12 Ctr1hrt/hrt mouse
liver and enterocytes back to WT levels (Figure 4.7). Because liver and intestine
ATP7A protein expression were not affected by ES treatment in WT mice liver
and intestine, this is a possible consequence of adequate Cu supply to heart tissues
via ES, which in turn downregulates the cardiac deficiency-triggered systemic Cu
homeostasis responses.
4.2.5 Intestinal CUA-1-associated lethality and embryogenesis de-
fects can be restored by ES treatment
ATP7A is crucial for dietary Cu transport from the intestine to peripheral
tissues, is required for Cu delivery to cuproenzymes in the secretary pathway. Mu-
tations in ATP7A can lead to the Cu-deficient Menkes disorder in humans. In C.
elegans, the ATP7A ortholog CUA-1 is expressed in the intestine, neurons, hypo-
dermis and pharynx, and is required for normal growth and embryogenesis under
dietary Cu-deficient conditions [126]. While RNAi depletion of cua-1 in wild-type
N2 worms resulted in lethality under low Cu conditions, it could be fully rescued by
ES supplementation into the culture media (Appendix Figure IV A). In addition, the
ES-treated cua-1 RNAi worms were able to generate similar brood sizes compared
to vector-treated worms (Appendix Figure IV B). Under all conditions, ES-treated
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Figure 4.7: ATP7A protein abundance in the liver and intestinal cells
from ES- or vehicle-treated Ctr1hrt/hrt mice. A) and C) ATP7A abundance
in P10-12 Ctr1hrt/hrt mice and WT littermates liver (A) and enterocytes (C) after
ES or vehicle (veh) injection. B) Quantification of liver ATP7A abundance from 5
individual experiments. D) Quantification of enterocyte ATP7A abundance from 3
individual experiments. ATP7A abundance was normalized to WT vehicle group
and present as fold change in panel C and D. Error bars represent mean ± SD.
Groups with different letters are significantly different from each other at p = 0.05
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worms yielded slightly more hatched progeny, indicating ES alone or ES-mediated
Cu delivery favors embryogenesis for worms grown under basal or Cu-deficient con-
ditions.
BK015 transgenic worms (Pvha-6::CUA-1.1::GFP; cua-1(ok904)) constitu-
tively express intestinal CUA-1 in a whole-body cua-1 knockout background. RNAi
depletion of cua-1 in BK015 results in lethality, which can be rescued by Cu sup-
plementation [126]. To further investigate the ability of ES to facilitate intestinal
Cu absorption in C. elegans, cua-1 RNAi was performed in BK015 strains. Syn-
chronized L1 larvae were plated on NGM media containing vehicle control or up to
500 nM of ES, or 1 µM CuCl2. After three days, live and dead worms were counted
and the survival percentage for each condition was calculated. Vector-treated worms
showed 25% survival under basal condition, while cua-1 RNAi worms were all found
dead (Appendix Figure IV C). The lethality could be rescued by addition of 1 µM
of Cu. ES treatment (> 250 nM) significantly rescued worm survival up to 85%,
and survival was fully restored to wild-type level by 500 nM of ES. Moreover, ES
significantly rescued the survival of vector-treated worms, suggesting the effect of
ES on Cu homeostasis in peripheral CUA-1-expressing tissues (Appendix Figure IV
D). These results strongly suggest ES could facilitate dietary Cu absorption into
the intestine and mediate Cu transport to peripheral organs, independent of CUA-1
expression.
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4.2.6 ES exhibits potential for Cu-transport through cultured blood-
brain-barrier cells
In Menkes patients and mottled mice, Cu cannot be effectively transported
from blood to neuronal tissues through the blood-brain-barrier (BBB) due to mu-
tations in ATP7A. Low Cu levels in the brain result in the dysfunction of several
cuproenzymes that are directly related to the neurological disorders and early fa-
talities observed in Menkes patients [190, 237]. In order to test whether ES is
capable of delivering Cu through the tight junctions of BBB cells, we used a well-
established BBB cell line co-culture system in vitro, the immortalized human cere-
bral microvascular endothelial cell (hCMEC/D3) [238, 239, 240]. Consistent with
previous reports, hCMEC/D3 cells exhibited trans-epithelial electrical resistance
(TEER) above 60 ohm.cm2 after several days of culture in the transwell insert, and
expressed several BBB tight junction proteins (Figure 4.8 A and B). The perme-
ability coefficient (Pe) of hCMEC/D3 to 4 kDa FITC-dextran in our culture system
was approximately 5-6 10-6 cm/s after 10 days of culture (Figure 4.8 C), which is
comparable to other reports [206, 241, 242, 243, 244]. We used the transwell co-
culture system to mimic the BBB in vitro, started with cultured hCMEC/D3 cells in
transwell inserts (referred to as the top well). After 10 days of culture, 0 or 7.5 nM
of ES, 20 µM CuCl2, or a combination of ES and Cu was added to the apical side
culture media of hCMEC/D3 cells. In the meantime, Cu-deficient Cr1 knockout
MEF cells (Ctr1-/-) were cultured in the bottom well. 24 hours after ES adminis-
tration, Ctr1-/- cells were collected and the CCS abundance was analyzed to check
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bioavailable Cu levels. Results indicated that ES administration to the apical side
of BBB cells alone significantly increased the bioavailable Cu levels in the Ctr1-/-
cells cultured on the basal side of BBB cells (Figure 4.8 D and F). Neither 7.5 nM
ES or 20 µM Cu affected ATP7A protein abundance of hCMEC/D3 cells (Figure 4.8
E and G). These findings suggest ES could facilitate Cu transporting through the
BBB tight junctions, which makes ES a promising treatment for Menkes-related
neuronal disorders. Future in vivo studies will be helpful to further evaluate the
permeability of ES to neuronal tissues.
4.2.7 Characterizing the effect of ES on tyrosinase activity in ATP7A-/-
cells
To assess the effect of ES on Cu delivery to cuproenzymes in the secretory
pathway, tyrosinase activity was evaluated in wild-type and ATP7A knockout MEF
cells (ATP7A-/-) upon ES supplementation. Because a high dose of ES could in-
hibit cell growth and cause cytotoxicity, non-toxic concentrations of ES were first
determined in MEF cells. Growth inhibition of MEF cells by ES was calculated by
the total number of live cells after 1 day of treatment with various concentrations
of ES. An effect on cell growth was observed upon treatment with 5 nM of ES, and
the IC50 of ES in MEF cells was close to 100 nM (Figure 4.9 A). Meanwhile, the
LD50 was not reached even with up to 7.5 µM ES treatment (Figure 4.9 B).
Transportation of Cu to tyrosinase is dependent on ATP7A protein activity, as
ATP7A-/- MEF cells transfected with a tyrosinase-expressing vector (pTyr) showed
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Figure 4.8: Apical ES treatment of BBB cells significantly increases Cu
levels of cells grown on the basal side. A) Transendothelial electrical resis-
tance (TEER) measurements of hCMEC/D3 cells grown on permeable transwell
plates. Approximately 4 x 106 cells were plated on day 0 on collagen-coated 6-well
inserts (surface area 4.67 cm2) and TEER values were measured on indicated days
after plating. N=2, error bars represent mean ± SD. B) Expression levels of tight
junction markers ZO-1 and Claudin-5 in BBB cells. C) Permeability coefficients of
hCMEC/D3 to 4 kDa FITC-dextran were measured on indicated days after plating
cells. Vehicle or ES was added to the apical side culture of hCMEC/D3 cells 24
hours before the assay. D) and E) 4 x 106 BBB cells were plated on collagen-coated
6-well transwell inserts. After 10 days, DMSO (Veh), 7.5 nM ES, 20 µM CuCl2 (Cu),
or ES plus Cu (ES+Cu) was added to the apical side culture media (upper well).
Simultaneously, Ctr1-/- MEFs were plated to the basal side of BBB (bottom well)
for 24 hours. Protein levels of CCS in Ctr1-/- MEFs and ATP7A in hCMEC/D3
were analyzed by immunoblottings. F) and G) Quantification of CCS and ATP7A
protein abundance from two independent experiments. Groups with different letters
are significantly different from each other at p = 0.05; ns, not significant (one-way
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no visible dopachrome formation (red color) after in-gel staining with the tyrosinase
substrate L-DOPA. Tyrosinase activity was highly increased by co-transfection of
ATP7A-/- cells with both tyrosinase and ATP7A (Figure 4.10). Because this dose of
ES was sufficient to rescue the mitochondrial function of Ctr1 -depleted MEF cells
in a previous study, 5 nM ES was added to wild-type and ATP7A-/- cell culture
media [175]. After 24 hours of ES treatment, ATP7A-/- cells showed no visible
tyrosinase activity (Figure 4.11 A and B). This may due to insufficient bioavailable
Cu in the tissue culture media or inside the ATP7A-/- cells for ES to interacted
with. To test this possibility, a higher dose of 30 nM ES, or 30 nM ES-Cu plus
10 µM CuCl2 was added to the culture media. However, dopachrome formation
still remained undetectable under these conditions in ATP7A-/- cells (Figure 4.11 C
and D). These results indicate a potential limitation of ES in delivering Cu into the
secretory pathway. In wild-type cells, 30 nM of ES or ES-Cu significantly increased
tyrosinase activity. This is likely due to increased intracellular Cu levels facilitated
by ES, which are then available to be transported to tyrosinase (or other secretory
pathway cuproenzymes) by ATP7A (Figure 4.11 C and D).
After treatment with 30 nM ES, total Cu levels in wild-type and ATP7A
knockout MEF cells were assayed by ICP-MS. After 24 hours of ES treatment, the
intracellular Cu levels remained unchanged in wild-type cells. Combined with pre-
vious findings, it is possible that excess Cu delivered into cells via ES was exported
out of cells by ATP7A. Because cells lacking ATP7A are defective in Cu efflux, in-
creased Cu levels in ATP7A-/- cells were observed compared to wild-type cells, and
ES treatment led to further Cu accumulation (Figure 4.9 C). These findings suggest
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ES may inefficient to transport Cu into the trans-Golgi network in the absence of
ATP7A.
4.3 Discussion
In mammals, an increased Cu requirement occurs during gestation and early
postnatal periods, when compared to adulthood [245]. Cu deficiency caused by low
dietary uptake, genetic polymorphisms or mutations and disease, could affect off-
spring from early postnatal stages, and result in dysfunction or diseased states in
several organs including the brain, heart, blood and immune systems [246, 247]. In
Drosophila and C. elegans, loss of Cu uptake due to Ctr1 ortholog protein dysfunc-
tion results in growth arrest at the early larvae stage, and could eventually lead
to death. In mice, whole-animal Ctr1 depletion is embryonic lethal [28, 176]. Our
results suggest Cu delivery via elesclomol to early larval C. elegans or perinatal mice
could rescue the early developmental arrest and lethality in chca-1 (tm6506 ) worms
and Ctr1hrt/hrt mice, respectively, supporting the critical role of Cu in embryonic
and neonatal growth and development. C. elegans CHCA-1 is highly expressed in
the intestine and hypodermis, and the growth retardation due to loss of this gene is
predominantly caused by its dysfunction in the intestine [233]. Based on the finding
that 50 µM ES was sufficient to rescue tm6506 mutant worm growth and Cu levels,
it is plausible that ES could facilitate dietary Cu absorption when the intestinal Cu
uptake mechanism is disrupted.
Results indicate that eight doses of ES administered from P5 to P26 at 10
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Figure 4.9: Effect of ES on Cu levels in wild-type and ATP7A-/- MEFs. A)
Total living wild-type MEF cells treated with increasing amounts of ES. Indicated
concentrations of ES were added to culture media for 24 hours before counting.
Asterisk marks indicate significant difference from untreated cells as determined by
one-way ANOVA (Sidak post hoc test, ∗∗∗p < 0.001). B) Viability of cells in panel
(A). (one-way ANOVA, sidal post hoc test, ∗p < 0.1, ∗∗∗p < 0.001). C) Cellular Cu
levels of WT and ATP7A knockout MEF cells after 24 hours of ES treatment (30
nM). Cu levels were normalized to protein abundance as measured by BCA assay.
Results present mean ± SD from three biological replicates under each condition,
and groups with different letters are statistically different from each other at p= 0.05
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Figure 4.10: ATP7A is required for tyrosinase activity. A) ATP7A-/- cells
were transfected with an ATP7A-expressing vector, and ATP7A and tyrosinase pro-
tein abundance were tested by immunoblot. Tyrosinase activity was determined by
the formation of dopachrome after in-gel staining with L-DOPA and 3-methyl-2-
benzothizzolinone (A). B) Quantification of tyrosinase in-gel staining activity by
Image J. Results from two independent experiments are presented, error bars repre-
sent mean ± SD. Groups with different letters are significantly different from each
other at p= 0.05 (one-way ANOVA, Sidak post hoc test).
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Figure 4.11: ES is insufficient to restore tyrosinase activity in ATP7A-/-
MEF cells. A) ATP7A+/+ and ATP7A-/- MEF cells were transiently transfected
with a tyrosinase-expressing vector pcTYR (Tyr +), or vehicle only (Tyr -), and
supplemented with 0 (-) or 5 nM ES in the culture media. (Upper panels) Represen-
tative immunoblots of ATP7A and tyrosinase (∼90 kDa) protein abundance from
three independent experiments. GAPDH serves as loading control. (Lower panel)
Tyrosinase activity on a native gel. Cells were lysed with buffer that does not con-
tain detergents or reducing reagent and lysates were then separated on a SDS-free
PAGE gel. Tyrosinase activity was colorimetrically determined by incubating gels
for 30-60 minutes at 37 °C in PBS solution containing 1.5 mM L-DOPA. B) Band
intensity quantification of tyrosinase activity from three independent experiments
by Image J. Error bars represent mean ± SD. Groups with different letters are
significantly different from each other at p = 0.05 (one-way ANOVA, Sidak post
hoc test). C and D) Experiments were performed using ATP7A-/- cells transfected
with a ATP7A-expressing vector, followed by treatment with 30 nM ES, or 30 nM
ES-Cu complex plus 10 µM CuCl2. (C) Representative immunoblot and tyrosinase
in-gel activity. (D) Band intensity quantification of tyrosinase activity from two
independent experiments. Error bars, mean ± SD. Groups with different letters are
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mg/kg to Ctr1hrt/hrt mice is sufficient to restore cardiac Ctr1 deficiency-related devel-
opmental defects. Heart and blood vessel abnormalities are common in Cu-deficient
animals, and cardiac hypertrophy has been observed in dietary Cu-deficient mice,
Ctr1hrt/hrt mice, and Ctr1int/int mice. ES administration is sufficient to rescue the
abnormal cardiomyocyte morphology, bioavailable Cu levels and Cco abundance in
the hearts of Ctr1hrt/hrt mice, suggesting ES-mediated Cu delivery into heart, in-
dependent of Ctr1. How does subcutaneously injected ES mediate Cu transport
to the heart? It has been reported that ES is able to bind Cu(II) from serum
or from ceruloplasmin, one of the major Cu-binding proteins in blood [150, 154].
Thus, it is plausible that injected ES diffuses into circulation where it interacts with
Cu(II) from Cu chaperone proteins such as ceruloplasmin or albumin and directs
Cu transport into the heart, providing sufficient Cu to cardiac mitochondria [248].
In addition to effects on the heart, ES treatment of Ctr1hrt/hrt mice also altered
systemic ATP7A responses back to wild-type levels. As ES specifically interacts with
Cu and ES treatment does not affect cardiac Ctr1 protein abundance, our results
support the notion that regulation of peripheral ATP7A protein abundance is not
directly due to cardiac Ctr1 ablation but a consequence of cardiac Cu deficiency.
Thus, the change of systemic ATP7A levels is likely a consequence of sufficient
cardiac Cu supply mediated by ES. It is possible that ES could also mediate Cu
delivery to other peripheral tissues besides the Cu-deficient heart. How ES treatment
affects other peripheral tissues Cu homeostasis is yet unknown. Will excess Cu
delivered via ES to Cu adequate tissues yield potential oxidative stress? Answers
to these questions require further investigation of ES-Cu transport mechanisms in
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vivo.
Whole-body Cu deficiency has been suggested to correlate with defects in
immune tissue development in animal models [235, 236]. However, observations of
small thymus and spleens in Ctr1hrt/hrt mice are unexpected, because unlike other
findings, the Ctr1hrt/hrt mice exhibit higher levels of Cu in the circulation. The
effect of cardiac Ctr1 depletion on thymus development may start during gestation,
as perinatal mice already have a pair of thymus formed in the final position above the
heart [249]. It is plausible that cardiac Cu deficiency is of higher priority in systemic
Cu homeostasis regulation, so Cu-dependent spleen and thymus development are
compromised under these conditions. Another explanation may be that a putative
signaling molecule generated from Cu-deficient heart is released into circulation, and
this signal directly or indirectly interferes with thymus and spleen development. How
thymus and spleen development are affected by cardiac Ctr1 ablation and how ES
rescues these tissues needs to be elucidated in the future.
Mutations in ATP7A can lead to a rare but severe Cu-deficient Menkes dis-
ease. The rescue of lethality and embryogenesis by ES treatment in the whole
body or intestinal cua-1 depleted worms strongly suggest the capability of ES to
facilitate intestinal Cu absorption and peripheral Cu distribution. Additionally, ES
revealed potency to facilitate Cu delivery through polarized BBB cells. Tight junc-
tions formed by brain endothelial cells have the highest electrical resistance and
lowest permeability to drugs compared to other body parts, and access of drugs
into the brain has been an important aspect in Menkes disease therapy evaluation
[250, 251, 252]. Our findings in worms and BBB cells shed light on using ES in the
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treatment of Cu-deficiency due to Menkes disease. It must be noted that results
from the tyrosinase activity assay highlighted potential limitations of ES treatment
in the delivery of Cu to cuproenzymes in the secretory pathway in the absence of
ATP7A. The efficacy of ES-Cu delivery to other cuproenzymes shall be further in-
vestigated in Menkes-derived cell culture models and mottled mice with reduced
ATP7A function, because regardless of total Cu levels in the brain or other tissues,
reduced function of cuproenzymes such as PAM and DBH can still lead to move-
ment and cognitive disorders in Menkes models. Drugs used in clinical research
reveal different affinities to varying subcellular compartments, and it has been re-
ported that ES preferentially transports Cu to the mitochondria [253]. However,
the mechanism is yet unknown. ES may be able to directly release Cu to other sub-
cellular compartments but with lower efficiency, or perhaps ES only drives Cu into
mitochondria, with smaller amounts of mitochondrial Cu being transported back
to the cytosol. Understanding subcellular ES-Cu transport mechanisms will benefit
future therapeutics.
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Chapter 5: Conclusions and future directions
5.1 Conclusions
1) Using sequence homology searches, 10 CTR candidate gene loci that express
15 unique proteins were identified in C. elegans. In general, worm CTR proteins
share 30–40 % identify with hCTR1. Similar to hCTR1, all candidates contain a
conserved Met–X3–Met domain close to the second TMD, and an extracellular N
terminus by topology prediction.
2) Transcription of candidate genes F58G6.3, F58G6.7, and F58G6.9 (chca-
1 ) was suppressed by Cu and elevated by Cu deficiency in axenic culture medium.
Expression of several other candidate genes was suppressed by high Cu but not
induced by low Cu at the transcriptional level.
3) The F58G6.9- (chca-1 ) and F27C1.2- depleted worms revealed developmen-
tal and embryogenesis defects when grown under Cu deficiency conditions on NGM
plates. Among candidate genes, chca-1 RNAi worms exhibited the most significant
defects in Cu accumulation under Cu-deficient conditions, suggesting chca-1 is re-
quired for Cu acquisition under low Cu conditions. However, expressing C-terminal
FLAG-tagged CHCA-1 did not rescue growth of CTR1∆CTR3∆ yeast, hinting that
Cu import in worms may involve other candidate genes in parallel to chca-1.
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4) In C. elegans lacking chca-1 expression, Cu-dependent CUA-1.1 intestinal
localization and CUA-1.1 hypodermal expression were similar to those worms grown
under Cu-deficient conditions, suggesting CHCA-1 is required for Cu acquisition and
maintaining systemic Cu levels.
5) Worms lacking chca-1 (chca-1 (tm6506) IV ) exhibited low body Cu accu-
mulation and defects in Cu acquisition. Similar to chca-1 RNAi, tm6506 animals
also revealed growth and embryogenesis defects, which can be rescued specifically
by Cu, but not other metals such as Fe, Mn or Zn. Taken together, these results
suggest that the function of chca-1 is Cu-specific.
6) Transgenic worms expressing GFP from the chca-1 promoter revealed that
chca-1 is predominantly expressed in the intestine and hypodermis, and that its
expression can be induced by Cu deficiency. Among the tissues in which chca-1
is expressed, intestinal CHCA-1 played a dominant role in regulating worm growth
and Cu acquisition. In addition, both intestinal and hypodermal CHCA-1 expression
may contribute to regulation of Cu balance at the organismal level, as tissue-specific
depletion of chca-1 did not alter intestinal CUA-1.1 trafficking. CHCA-1 protein
localizes to intracellular vesicles in the intestine, as indicated by both GFP and
FLAG-tagged fusion versions of the protein, and the fusion protein abundance was
not regulated by Cu availability.
7) C. elegans exhibit behavioral avoidance when Cu is present in toxic con-
centrations. Worms lacking chca-1 expression showed reduced levels of avoidance,
suggesting chca-1 is required for sensing toxic Cu. The reduced avoidance was re-
capitulated in dietary Cu-deficient worms, suggesting that abnormal body Cu levels
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correlate with changes in Cu sensing and avoidance behavior. It is important to
note that Cu-dependent neuropeptide maturation is crucial for normal Cu-sensing
behavior in C. elegans. This is supported by defective avoidance behavior when
RNAi knockdown depletes egl-3, egl-21, and PAMs in worms.
8) The addition of ES rescued the growth defects of tm6506 worms cultured
under Cu-deficient conditions as well as body Cu levels in these animals. In addi-
tion, ES supplementation to whole-body or intestinal-specific cua-1 -depleted worms
significantly rescued the lethality and embryogenesis defects, suggesting that ES is
able to mediate dietary Cu uptake and peripheral tissue Cu transport through the
intestine when dietary Cu acquisition mechanisms are disrupted.
9) Subcutaneous injection of ES to Ctr1hrt/hrt mice from P5 to P26 was suf-
ficient to rescue postnatal lethality and decreased body mass of the mutant mice.
The cardiac hypertrophy, abnormal thymus and spleen development were also re-
stored to wild-type level upon ES treatment. ES itself did not affect Ctr1 or ATP7A
protein expression.
10) Total and bioavailable Cu levels in Ctr1hrt/hrt mouse hearts were signif-
icantly increased after ES administration. ES treatment until P54 fully restored
cardiac mitochondrial Cox1 abundance in mutant mice. These findings suggest that
ES could mediate Cu delivery to cardiac tissues of Ctr1hrt/hrt mice and rescue the Cu
deficiency and mitochondrial dysfunction observed in the hearts of these mice. In
addition, the systemic Cu homeostasis responses in the cardiac Cu-deficient mice,
indicated via the induction of ATP7A expression in the liver and intestine, were
reduced back to normal levels after two ES treatments on P5 and P8.
139
11) Administration of ES to the apical side of cultured BBB cells was able
to rescue the Cu deficiency in Ctr1-/- cells grown on the basal-side of BBB, with-
out altering BBB cells ATP7A protein abundance, suggesting that ES can mediate
Cu transport through BBB tight junctions. Meanwhile, our studies in cultured
ATP7A-/- cells raised a potential limitation of ES to effectively delivery Cu to ty-
rosinase in the secretary pathway, as ES or ES-Cu supplementation failed to increase
tyrosinase activity in ATP7A-/- cells.
5.2 Future Directions
5.2.1 Characterizing C. elegans CTR ortholog genes
Based on chca-1 tissue expression patterns, subcellular localization and its re-
quirement during Cu deficiency, other Cu uptake mechanisms likely exist in parallel
to chca-1 to direct Cu to other tissues (including neurons and the pharynx), and
across the apical surface of intestinal cells. Several CTR genes such as F31E8.4
and Y58A7A.1 complemented the growth of CTR1 ∆CTR3 ∆ yeast in YPEG me-
dia, suggesting a role for these CTR genes in Cu transport. Further tests can be
conducted in Ctr1-/- cells expressing candidate genes to confirm and quantify their
Cu transport activity with radiolabeled Cu.
Although using RNAi to individually deplete other CTR candidate genes does
not significantly affect body Cu accumulation or intestinal CUA-1 trafficking, Ctr
proteins may function together to mediate Cu uptake. To test this possibility, RNAi
can be applied to multiple candidate genes simultaneously, and body Cu levels, Cu-
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dependent growth, and intestinal CUA-1 localization can be analyzed. It is also
worth noting that, most experimental results in this study were collected at the
L4-young adult stage; it will also be necessary to characterize the stage-specific
expression pattern of candidate genes, as Cu acquisition may require multiple CTR
genes expressed under different developmental stages.
Though several C. elegans CTR candidates did not reveal Cu-dependent regu-
lation at the transcriptional level, such regulation may occur at the translational or
post-translational levels, or perhaps Cu availability might affect the protein local-
ization. Generating translational fusion worms that express GFP-tagged versions
of the candidate genes driven by their endogenous promoters will help in the char-
acterization of their Cu-dependent responses. Moreover, organisms may maintain
a constant rate of Cu uptake regardless of Cu availability. Thus, Cu-dependent
regulation may not occur for every C. elegans CTR gene. This would be similar to
Drosophila Ctr1A, a Ctr ortholog ubiquitously expressed through development and
into adulthood, the expression of which is not affected by Cu availability.
5.2.2 Identifying the neuronal components required for Cu sensing
in C. elegans
Our results suggest that body Cu status and Cu-dependent maturation of
neuropeptides both play a role in Cu sensation and avoidance behavior in C. elegans.
C. elegans has been used for many such studies as neuronal signaling pathways are
well conserved between humans and worms [254, 255]. Several sensory neurons such
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as ADL and ASH and the interneuron RIC have been reported to to involved in the
sensation of hazardous stimuli (including Cu) in worms [212, 213, 256]. Thus, C.
elegans would serve as an excellent tool to decipher the role of neuropeptides in Cu
avoidance behavior, and to identify conserved neuronal components required for Cu
sensation.
C. elegans contains 119 genes that encode more than 250 neuropeptides. An
RNAi-based Cu avoidance screening can be performed on the neuropeptide coding
genes to identify candidates involved in Cu-induced avoidance behavior. The Cu
specificity of candidate peptides would be further tested with gradient plates gen-
erated by other heavy metals such as iron, cobalt and cadmium. The functions
of candidates could be confirmed with the loss of function mutant strains already
available or generated by CRISPR-Cas9.
In order to determine the sensory/inter-/afferent neurons where the candidate
neuropeptides express and affect neuronal activities, transcriptional and transla-
tional fusion reporters can be generated for candidate peptides to identify the sites
of expression and regulation by Cu. Next, calcium flow experiments can be per-
formed under Cu stimuli to determine the neuronal activities in these candidate
peptides-expressed neurons, and the requirement of these neurons in Cu-sensing
behavior could be further confirmed using photo-inducible cell ablation [257].
Neuropeptides commonly rely on G-protein coupled receptors or neuropep-
tide receptors to trigger downstream signaling pathways, and many neuropeptides
receptors have been identified. If candidate peptides have known or putative recep-
tors, the requirement of these candidate peptides in Cu sensation can be directly
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determined using RNAi knockdown and the avoidance assay.
5.2.3 Elucidating elesclomol-mediated Cu transport in mouse
Our results show that ES-mediated Cu transport into the hearts of Ctr1hrt/hrt
mice restores Cu levels and suppresses cardiac hypertrophy. Aberrant ATP7A ex-
pression in peripheral tissues in response to cardiac Cu deficiency was also returned
to wild-type levels by ES treatment. Precisely how ES affects regulation of systemic
Cu homeostasis remains an important question to answer. According to previous
studies, ES can bind Cu in the serum and then enter cells by diffusion in the form of
an ES-Cu complex. How effective ES-mediated Cu transport to tissues other than
the heart can be determined by measuring the presence of ES in these tissues shortly
after ES administration, as ES is rapidly eliminated from the plasma with a half-life
of ∼ 1 hour in vitro [139, 140]. Do different tissues exhibit distinct affinities for
ES-Cu uptake? Is the ES-Cu membrane diffusion rate affected by ES or Cu concen-
tration gradients? If a Cu concentration gradient drives ES-Cu diffusion, then Cu
transport may be prioritized to Cu-deficient tissues such as the heart and liver in
Ctr1hrt/hrt mice, and less so to other tissues not affected by cardiac Cu deficiency (for
example, the muscle and brain). It is also possible that multiple peripheral tissues
may obtain ES-Cu simultaneously, as long as cells of these tissues are permeable
to the ES-Cu complex. To address these questions, time-dependent tissue Cu accu-
mulation in varying tissues during ES treatment can be analyzed in both wild-type
and Cu-deficient mice models (such as Ctr1hrt/hrt mice and mottled mice). Positron
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emission tomography (PET imaging) can be used to trace ES-64Cu trafficking and
time-dependent tissue accumulation in mice [258, 259]. Cu overloaded ATP7A-/-
cells that lack Cu efflux may also be useful to monitor ES-mediated radio-labeled
Cu import/export.
In addition, though abnormal development of the thymus and spleen in Ctr1hrt/hrt
mice may involve systemic Cu sequestration regulation and unknown signaling path-
ways, analyzing the Cu levels and cuproenzymes activities in these tissues before
and after ES administration would provide valuable information to establish the
correlation between underdeveloped tissue and Cu deficiency.
5.2.4 Evaluation of elesclomol treatment using Menkes disease mod-
els
Mottled mice provide a useful in vivo model for pre-clinical drug testing for
Menkes disease. The macular , mosaic, and brindled mutation strains are postnatal
lethal within three weeks and would be beneficial to determine the efficacy of ES
treatment during early postnatal stages. ES can be introduced through subcuta-
neous or intravenous injection to new-born mice until Cu-dependent development
has been completed. Body mass, survival rates and disease-related phenotypes such
as kinky whiskers and pigmentation may be monitored.
If ES can rescue Menkes mice body mass and lethality, further analysis shall
be performed to examine Cu distribution among tissues and Cu-related neuronal
functions after ES treatment. Circulating Cu levels and Cu distribution in periph-
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eral tissues such as the heart, brain and liver can be assayed by ICP-MS, and the
cuproenzymes activities such as Cco, DBH can be tested simultaneously. Assess-
ments of motor balance, coordination, muscle strength and locomotive activity can
also be performed on ES-treated mottled mice [260, 261].
Though our studies reveled limitations to the ability of ES to effectively assist
incorporation of Cu into tyrosinase in ATP7A-/- MEF cells, further experiments us-
ing Menkes patient-derived cells and mottled mice could provide more thorough and
clinically-relevant information regarding the efficacy of ES-mediated Cu transport
into the secretary pathway. Because neuronal Cu abundance and Cu-dependent
enzyme activity has been the main focus in evaluating Menkes therapies, it would
also be necessary to characterized other cuproenzymes such as Cco, DBH and PAM
activities in these future studies.
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Appendix
I Transcriptional regulation of C. elegans CTR1 candidate genes by
Cu
Figure I: A) Cu-dependent C. elegans growth in axenic media. Total worm numbers
were calculated for three independent experiments. Asterisks indicate significant
difference from optimal 10 µM CuCl2 condition (One-way ANOVA, Dunnett post
hoc test, ∗∗p< 0.01,∗∗∗∗ p< 0.0001). B) and C) qRT-PCR analysis of C. elegans CTR
candidate genes under Cu-limited (B) and high Cu (C) conditions. Worms were
synchronized and supplemented with 100 µM BCS, 10 µM CuCl2 or 300 µM CuCl2
from L1 to L4 stage in axenic media. Individual gene expression was normalized first
to pmp-3, then to its own expression under Cu-optimal conditions. Two independent
experiments were conducted under each condition. Asterisks indicate significant
difference from indicated gene expression levels under optimal conditions. (Two-
way ANOVA, Sidak post hoc test, ∗p < 0.05,∗∗∗ p < 0.001,∗∗∗∗ p < 0.0001). Error
bars, mean ± SEM. This figure is contributed by previous lab member Alexandria
Richart.
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II Cu-dependent neuropeptide maturation is associated with Cu avoid-
ance behavior
Figure II: A) Avoidance index of RNAi-hypersensitive worms (TU3335) lacking the
egl-3 or egl-21 gene on 10 mM Cu gradient plates. Error bars indicate mean ± SEM
of eight independent experiments under each condition. Values with asterisks are
significantly different from each other (One-way ANOVA, Dunnett post hoc test,
∗p < 0.05,∗∗ p < 0.01,∗∗∗∗ p < 0.0001). B) PAM genes (pgal-1, pghm-1 and pamn-
1 ) were co-depleted by RNAi for two consecutive generations in TU3335 strain,
followed by the avoidance assay on 10 mM Cu-gradient plates. Error bars indicate
mean ± SEM of two independent experiments. Values with asterisk are significantly
different (One-way ANOVA, Dunnett post hoc test, ∗p < 0.05,∗∗ p < 0.01). This
figure is contributed by the previous lab member Anuj Sharma.







































































III Cox1 abundance in P10 Veh/ES administered Ctr1hrt/hrt mice.
Figure III: Left:Cco component Cox1 abundance of P10 cardiac tissues from three
independent experiments. ATP5A was used as loading control. One-way ANOVA,
Sidak post hoc test. Error bars represent mean ± SD. This figure is contributed by
Shivatheja Soma, Texas A&M University.
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Figure IV: A) (top row) Wild-type worms (N2 strain) were exposed to RNAi from
the L1 stage for 4 days with or without 100 µM BCS treatment in the presence
of vehicle (DMSO); (bottom row) worms grown under identical conditions as above
supplemented with 5 µM ES. Representative microscope images from three indepen-
dent replicates are shown; arrowheads indicate dead worms. B) Wild-type worms
(N2 strain) grown under varying RNAi and BCS conditions supplemented with vehi-
cle (DMSO) or 5 µM ES were picked to individual plates at the L4 stage in triplicate,
allowed to lay eggs, and transferred to fresh plates every 24 h for 3 days. Eggs were
incubated overnight to allow hatching and progeny number was determined as the
total hatched larvae, n= 3 biological replicates (∗∗∗∗p < 0.0001,∗∗ p < 0.01; two-way
ANOVA, Tukey’s post hoc test). Error bars represent mean ± SEM. C) Trans-
genic worms [BK015 strain, Pvha-6::CUA-1.1::GFP::unc-54 3’UTR; cua-1(ok904)]
were cultured on RNAi plates supplemented with either vehicle (DMSO), 1 µM
Cu, or 5 µM ES from the L1 stage for 4 days. Representative microscope im-
ages from three independent replicates are shown; arrowheads indicate dead worms.
D) BK015 strain worms were cultured on RNAi plates supplemented with either
vehicle (DMSO) or 5 µM ES from the L1 stage for 4 days and then scored for
survival. Animals were considered dead when no signs of viability (movement, pha-
ryngeal pumping, or response to prodding) were detected, n= 3 biological replicates
(∗∗∗∗p < 0.0001,∗∗∗ p < 0.001,∗∗ p < 0.01 when compared with vehicle control condi-
tion; two-way ANOVA, Bonferonni’s post hoc test). Error bars represent mean ±
SEM. This figure is contributed by Tamara Korolnek.
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IV Primers used for qRT-PCR assays
Table I: Primers labeled with ∗ were redesigned outside of the RNAi construct
targeting region, in order to test the RNAi effectiveness.
























V List of transgenic animals used in Chapter 3
Table II: List of transgenic animals used in Chapter 3.
Strain Name Background Transgene
BK058 unc-119 (ed3) III PF58G6.9::GFP::unc-54 3’UTR; unc-119 rescue
BK059 N2 Pvha-6::CHCA-1::GFP::unc-54 3’ UTR
BK060 CHCA-1 (tm6506) IV Pvha-6::CHCA-1::GFP::unc-54 3’ UTR
BK061 N2 Pvha-6::CHCA-1::SL2:GFP::unc-54 3’ UTR
BK062 CHCA-1 (tm6506) IV Pvha-6::CHCA-1::SL2:GFP::unc-54 3’ UTR
BK063 N2 Pvha-6::CHCA-1-2xflag::SL2:GFP::unc-54 3’ UTR
BK014 N2 Pvha-6::CUA-1.1::GFP::unc-54 3’ UTR
BK015 cua-1 (ok904) III Pvha-6::CUA-1.1::GFP::unc-54 3’ UTR
BK017 cua-1 (ok904) III Pcua-1::CUA-1.1::GFP::unc-54 3’ UTR
WM27 rde-1(ne219) V -
VP303 rde-1(ne219) V Pnhx-2::RDE-1; rol-6 marker
NR222 rde-1(ne219) V Plin-26::nls-gfp; Plin-26::RDE-1; rol-6 marker
WM118 rde-1(ne300) V Pmyo-3::HA::RDE-1; rol-6 marker
BK027 rde-1(ne219) V Pvha-6::CUA-1.1::GFP::unc-54 3’ UTR
BK033 rde-1(ne219) V Pvha-6::CUA-1.1::GFP::unc-54 3’ UTR; Pnhx-2::RDE-1; rol-6 marker
BK022 rde-1(ne219) V Pvha-6::CUA-1.1::GFP::unc-54 3’ UTR; Plin-26::RDE-1; rol-6 marker
TU3335 lin-15B (n744) X Punc-119::SID-1; Punc-119::YFP; Pmec-6::MEC-6
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